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Summary 
3D cell culture is supposed to mimick a tissue-like environment found in-vivo and it is used to 
study molecular and biochemical aspects of many physiologic functions under in-vitro 
conditions. A key regulatory pathway of important cellular functions such as ribosomal 
biosynthesis, proliferation, metabolism and cell size is the mammalian target of rapamycin 
(mTOR) pathway. It was previously extensively studied using monolayer culture, however 
mTOR signalling has not been studied very well in cells cultivated in 3D. Since the 
environment and the shape of cells can determine its behaviour and gene expression, we 
wanted to identify differences between 2D and 3D culture in respect to mTOR signalling. 
Furthermore we were interested in the invasion potential of fibroblasts in collagen gels under 
these experimental settings. After establishing culture conditions for IMR-90 lung fibroblasts 
in collagen gels and a harvesting protocol, cells from 2D and 3D culture were subjected to 
FACS analysis and DNA content and cell size was determined. Spheroid invasion assays 
were performed in the presence of the specific mTOR inhibitor rapamycin and siRNA 
mediated knockdowns of raptor- and rictor, two components of different mTOR multiprotein 
complexes. Immunofluorescence analyses were done with antibodies for mTOR pathway 
components, α-phospho Histone H3 and α-cleaved caspase-3. We found a massive cell size 
reduction, less proliferation and changes in the granularity in fibroblasts cultivated in 3D as 
compared to cells in 2D. Altered cell size and cell cycle distribution indicate changes in the 
mTOR pathway, however immunofluorescence analyses did not show significant differences 
in the amount or activity of the proteins. Some mTOR pathway components were altered in 
respect to localisation, e.g. pAKT (S473) displayed a more vesicular like distribution and 
total AKT protein was upregulated within the nuclei in fibroblasts cultivated in 3D. 
Furthermore cells cultured in collagen gels displayed reduced invasion after treatment with 
rapamycin and transfection with raptor and rictor siRNA. The invasive properties of the IMR-
90 cells were profoundly reduced upon rictor knockdown, whereas raptor knockdown 
displayed an intermediate effect. Immunofluorescence analysis showed induction of apoptosis 
in rapamycin treated spheroids as demonstrated by an increase in the proportion of early 
apoptotic (cleaved capase-3+) and late apoptotic (cleaved caspase+/condensed nuclei+) 
fibroblasts.  
In summary we found profound alterations in fibroblasts cultivated in 3D as compared to 2D 
and an influence of mTOR signalling in the invasive properties of IMR-90 fibroblasts, 
however, further quantitative evaluation of the mTOR pathway (e.g. by Western blot 
analysis) is needed to determine the molecular events leading to reduced cell cycle 
progression and size as well as to a decrease in invasive capacity upon mTOR inhibition. 
Zusammenfassung 
3D-Zellkultur wird verwendet, um eine gewebeähnliche Umgebung, wie sie in-vivo zu finden 
ist, nachzuahmen. Ein weiterer Verwendungszweck ist die Untersuchung von molekularen 
und biochemischen Aspekten vieler physiologischer Funktionen unter in-vitro Bedingungen. 
Der „mammalian target of rapamycin (mTOR)-pathway” ist ein wichtiger Signalweg der 
Zellen, der essentielle Funktionen wie ribosomale Biosynthese, Zellteilung, Stoffwechsel und 
Zellgröße kontrolliert. Dieser wurde bisher ausführlich in Monolayerkulturen untersucht, 
jedoch nicht in Zellen in 3D Kultur. Da die Form und die Umgebung der Zellen ihr Verhalten 
und ihre Genexpression bestimmen können, wollten wir Unterschiede zwischen Fibroblasten 
aus 2D- und 3D-Kultur, in Bezug auf den mTOR-Signalweg, identifizieren. Weiters waren 
wir an ihrem Invasionspotenzial innerhalb der Kollagen-Gele interessiert. Nachdem wir die 
Kulturbedingungen für IMR-90 Fibroblasten in Kollagen-Gelen und ein Isolations-Protokoll 
etablierten, wurde der DNA-Gehalt und die Zellgröße von Zellen aus 2D- und 3D-Kultur mit 
Hilfe von FACS-Analyse bestimmt. „Spheroid invasion assays“ wurden unter Anwesenheit 
des spezifischen mTOR Inhibitors Rapamycin und siRNA vermittelter knock-downs von 
Raptor und Rictor, den Komponenten zweier unterschiedlicher mTOR Multiproteinkomplexe, 
durchgeführt. Immunfluoreszenz-Analysen wurden mit Antikörpern gegen mTOR 
Komponenten, phospho Histone H3 und cleaved caspase-3 durchgeführt. Im Unterschied zu 
2D fanden wir in Fibroblasten aus 3D- Kultur eine massive Reduktion der Zellgröße, 
geringere Zellteilung und Veränderungen in der Granularität. Veränderte Zellgröße und 
Zellzyklusverteilung weisen auf Änderungen des mTOR-Signalweges hin, 
Immunfluoreszenzanalysen zeigten jedoch keine signifikanten Unterschiede in der Menge 
oder der Aktivität der beteiligten Proteine. Einige Komponenten des mTOR-Signalweges 
waren in Bezug auf ihre Lokalisation in den Fibroblasten verändert, z. B. pAKT (S473), 
welches eine vesikulärere Verteilung zeigte und das Totalprotein AKT, das innerhalb der 
Kerne in 3D Kultur hochreguliert war. Weiters zeigten in Kollagen-Gelen kultivierte Zellen 
reduzierte Invasion nach Behandlung mit Rapamycin und Transfektion mit Raptor und Rictor 
siRNA. Die invasiven Eigenschaften von IMR-90 Zellen wurden nach Behandlung mit Rictor 
siRNA hochgradig reduziert, während die Transfektion mit Raptor siRNA eine mittelgradige 
Wirkung zeigte. Immunfluoreszenz-Analyse zeigte eine Induktion von Apoptose in 
Rapamycin behandelten Sphäroiden durch einen erhöhten Anteil von früh (cleaved capase-3+) 
und spät apoptotischen (cleaved caspase-3+/kondensierten Kernen+) Fibroblasten. 
Zusammenfassend stellten wir Veränderungen in Fibroblasten aus 3D-Kultur verglichen mit 
2D-Kultur fest. Weiters fanden wir Einflüsse des mTOR-Signalweges auf die invasiven 
Eigenschaften von IMR-90 Fibroblasten, allerdings werden noch weitere quantitative 
Auswertungen des mTOR-Signalweges (zB durch Western-Blot-Analyse) benötigt, um die 
molekularen Mechanismus, die zu reduzierter Zellgröße und Zellzyklus Verteilung, sowie zu 
einem Rückgang der invasiven Kapazität durch mTOR-Hemmung führen, zu bestimmen. 
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1.1 What are fibroblasts? 
1.1.1 Fibroblast origin and function 
Fibroblasts are mesenchymal cells, mostly residing in connective tissue, which consists in 
addition to fibroblasts of fat cells, macrophages, eosinophilic granulocytes, lymphocytes, 
melanocytes and mast cells embedded in extracellular matrix (ECM). Connective tissue 
encloses organ structures (then called stroma) and is located throughout the whole body. 
ECM itself consists of basic components (hyaluronic acids, proteoglycans, glycoptoteins), 
collagen and elastin fibres [1]. Fibroblasts are responsible for the synthesis of collagen in 
the ECM and are concomitantly regulated by changes in the composition of ECM, leading 
to interactions with integrins stimulating fibrogenesis (cell proliferation, migration, ECM 
deposition). Further functions are implicated in i) wound healing, which is a universal 
response to injury-following inflammation, ii) regulation of epithelial differentiation and 
iii) inflammation regulation ([2]; reviewed in [3, 4]). During wound healing after 
cutaneous injuries, fibroblasts migrate quickly to the wound environment, thereafter start 
to proliferate and produce ECM proteins (collagen and fibronectin) [3]. Fibroblasts are 
connected with various diseases like fibrosis [3, 5], keloid formation [6], diseases caused 
by deficient or abnormal collagen (scurvy [7], Ehlers-Danlos syndrome [8]) and cancers 
(cancer-associated fibroblasts, reviewed in [4]). 
 
1.1.2 Fibroblast morphology 
Fibroblasts display a spindle-shaped pattern in-vivo, cultured on plastic surfaces of tissue 
culture plates they show a dendritic morphology, with large and euchromatic nuclei. They 
are characterised as non-vascular, non-epithelial and non-inflammatory cells, defined by 
the lack of certain markers for other cell lines, such as epithelial, smooth muscle, 
endothelial, perineural and histiocytic cells (reviewed in [4, 9-11]). There are well-
established markers for fibroblasts, but none of these are expressed exclusively or in all 
fibroblasts. E.g. vimentin is found in all fibroblasts and in neurons, endothelial and 
myoepithelial cells or desmin, which is only present in skin fibroblasts and in other cell 
lines like muscle and vascular smooth muscle cells (reviewed in [4]). 
The cells, which were used for the experiments in this study, are primary human lung 
fibroblasts. They are derived from a human female fetus with a gestation age of 16 weeks 
[12]. At this time the fetal lung transits from the pseudoglandular to the canalicular stage 
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(see below). The fibroblasts reside in a dense three-dimensional (3D) ECM, surrounding 
the developing alveoli (see Figure 1.1 and chapter 1.1.3). 
Fibroblasts possess a topographic memory. This was demonstrated using fibroblasts from 
different sites of various donors and full genome covering cDNA microarrays [9]. 
Unsupervised hierarchical cluster analysis showed that fibroblasts were grouped 
according to their sites of origin rather than depending on the individual they are derived 
from. Also different passages were grouped together, showing that the gene expression 
patterns are stable under culture conditions [9]. These results let us hypothesize that the 
fibroblasts used for the experiments in our study display very similar expression patterns 
as compared to the in-vivo situation. 
 
1.1.3 Fetal lung development 
Lung development can be classified in four histological stages, the pseudoglandular, the 
canalicular, the terminal saccular and the alveolar stage [13]. The first one is the 
pseudoglandular stage from 5-17 weeks of human pregnancy (E9.5-16.6 days in mouse 
embryo). During this stage branching morphogenesis of epithelial tubes generates 
terminal bronchioles and epithelial gland-like structures are formed, which are embedded 
in a rapidly proliferating mesenchyme (or stroma) containing predominantly fibroblasts 
(see Figure 1.1). In the canalicular stage from 16-25 weeks (E16.6-17.4 days) the 
respiratory tree undergoes further size expansion accompanied by vascularisation and 
angiogenesis within the surrounding stroma, leading to a massive increase of capillaries. 
The airway epithelial cells differentiate into peripheral squamous cells and proximal 
cuboidal cells and the terminal bronchioles divide into respiratory bronchioles and 
alveolar ducts. This stage partially overlaps with the pseudoglandular stage, due to the 
faster developing cranial part of the lung. The terminal saccular stage, from 24 weeks to 
late fetal period (E17.4 to postnatal day 5 (P5)), is accompanied by thinning of the 
interstitium due to further differentiation of mesenchymal cells and apoptosis. The 
capillaries grow into the mesenchyme and form a dense network. At the end of this stage 
air-exchange is possible. The last part of fetal lung development is the alveolar stage from 
the late fetal period to childhood (P5-P30), it is characterised by alveolarisation, where 
the largest part of surface for gas-exchange is formed (reviewed in [13]).  
The adult lung interstitium contains fibroblasts, collagen type I and III and elastin, 
whereas alveolar and lung basement membranes (BM) predominantly consist of collagen 
type IV and laminin [3]. 
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Figure 1.1: The image shows the pseudoglandular stage of a mouse embryonic lung (E14.5). The arrow 
marks the rapidly proliferating mesenchyme, which educes fibroblasts. 
(Picture taken from [13]) 
 
 
1.2 3D cell culture  
3D cell culture is a useful tool to study physiological aspects of many cellular features 
e.g. biomechanical functions, like cell-matrix interactions, under in-vitro conditions. It is 
supposed to allocate a tissue like environment mimicking the ECM features, which are 
found in-vivo, since the environment and the shape of a cell can determine behaviour and 
gene expression [14]. There are many examples for the more physiologic behaviour of 
cells cultured in a 3D environment, a few of which will be described below. T47D breast 
epithelial cells cultured in monolayer are not able to differentiate into duct-like tubules 
until they are transferred into floating collagen gels and subsequently undergo 
tubulogenesis [15]. In-vivo nutrient exchange in epithelial cells occurs normally through 
their basolateral surface, cultivation on tissue culture plates restrict this access due to the 
attachment of the basal side of the cells with the culture dish and the presence of tight-
junctions and desmosomes between the cells. Whereas the culture of epithelial cells on 
microporous membranes allow metabolic processes, like they occur in-vivo through their 
basal membrane and result in a more differentiated phenotype of the cells [16-18]. Mouse 
mammary gland cells cultured on uncoated or collagen coated tissue culture plates 
synthesise only minor amounts of β-casein (a major milk protein), whereas those cells 
cultivated on top of a floating collagen gel regain their in-vivo morphology and 
expression of β-casein caused by stimulation of BM formation, leading to upregulation of 
β-casein synthesis. The same effect occurs when cells are cultivated directly on a BM gel. 
(reviewed by [19]). Cells from a metastatic melanoma cultured as monolayer on 2D 
display profound modifications of the gene expression compared to cells cultivated in 
multicellular spheroids [20]. Two gene products (CXCL1 (GRO-α) and IL-8), which are 
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involved in melanoma progression and metastatic processes, are significantly upregulated 
in spheroid culture [20]. 3D cell culture enables co-cultivation of different cell types, and 
cells in different states like proliferating, nonproliferating and necrotic cells (reviewed in 
[21]).  
 
1.2.1 Fibroblasts in 3D 
Fibroblasts can also be cultivated under more physiologic conditions than on plastic 
surfaces. When fibroblasts are embedded in collagen gels, they adopt morphologies 
varying from bipolar spindle forms to dendritic forms [11]. This depends on the matrix 
tension and stiffness. Fibroblasts in floating collagen gels (gels, which are released from a 
solid support, mostly the plastic surface onto which they have been poured, after cells are 
embedded) start to remodel the ECM due to their motile activity. The cells do not show 
stress fibers and a dendritic phenotype, this morphology can be observed in-vivo during 
quiescence and apoptosis. In attached collagen gels the matrix stiffness is higher than in 
released ones. Cells show a bipolar pattern with actin stress fiber development and 
cytoskeletal reorganization, which also occur during the process of wound healing [14, 
22]. 
When fibroblasts are cultured in a collagen gel, the cells contract the ECM. The resulting 
gel is dense, has an opaque body and is less than 1/10 of the original size [11]. The 
collagen density can increase from 1.5 mg/ml to 20 mg/ml, which is equal to the density 
of collagen in tissue [23]. Collagen gels without cells do not shrink even after a week of 
cultivation, indicating that the reason for the contraction is only the presence of 
fibroblasts. Experiments showed that the rate of contraction is dependent on the amount 
of cells, which are embedded in the gel [24]. 
Culturing of fibroblasts in cell aggregates leads to a programmed activation of a pathway 
called nemosis. This results in activation of growth factor secretion and the induction of 
proinflammatory and proteolytic responses that cause a programmed necrosis-like cell 
death (reviewed in [25]). After 24 hours of cultivation fibroblast spheroids start to 
decompose, the volume decreases and after 120 hours only remnants of dead cells and 
debris are left [26]. Ultrastructural features are compatible with necrosis, like the pyknotic 
nuclei whereas the loss of nuclear membrane integrity is lacking. The main difference to 
necrosis is that nemosis does not occur accidentally but seems to be executed in a 
programmed manner like apoptosis. Differences to apoptosis are that nemosis is executed 
without caspase-3 activation and DNA fragmentation (reviewed in [25]). 
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Cells, which undergo nemosis, show a massive induction of cyclooxygenase-2 (COX-2), 
which is usually absent in most normal tissues but has been shown to increase the 
metastatic potential in colon cancer cells. COX-2 shows an even expression throughout 
the spheroid, showing that nutrient deprivation and hypoxia in the centre are not the 
reasons for its increase (reviewed in [25]). Experiments showed that the caspase inhibitor 
Z-VAD-FMK reduces COX-2 expression and inhibits membrane damage, this suggests 
that nemosis is not executed caspase-independently [26]. 
 
1.2.2 3D culture methods 
There are different methods to cultivate cells in a 3D environment. The appropriate 
method to use depends on the scientific question, since not all problems can be addressed 
with the same model [15, 27]. In the following chapters different methods for 3D cell 
culture, tumour cell culture and co-culture of tumour cells and stromal cells are 
summarised.  
 
Spontaneous cell aggregation 
This method uses non-adherent culture plates, which prevent cell-surface attachment. 
Within this cultivation tumourigenic cells show a much higher self-aggregation rate to 
form sphere like structures (spheroids) than non-transformed cells [28]. 
 
Liquid overlay culture 
For this method cell culture tissue plates with a layer of agar, agarose or reconstituted BM 
like Matrigel® are used to avoid cell attachment to the plastic surface. Cells are thereafter 
seeded on top of the surface of the coated dishes, which induces the formation of 
spheroids. For studying individual spheroids this method is widely used ([29]; reviewed 
in [21]). Under these conditions primary cells from a mouse lung and tumour cells are 
able to form aggregates; but only tumour cell aggregates are capable to grow, unlike these 
primary lung cells, which break apart after three days [29].  
 
Filter well inserts 
Filter well inserts are microporous filter membranes inserted in culture vessels like 24-
well plates forming an upper and lower compartment filled with growth medium [18]. 
Cultivation of epithelial cells on these membranes allows the apical and also the basal 
membrane to interact with the environment, whereas this interaction of the basal 
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membrane is not possible in normal tissue culture plates [16]. This metabolic process 
recapitulates the in-vivo situation more likely than in 2D [18]. 
 
Spinner flask culture, gyratory rotation culture, rotating-wall vessel culture 
For cultivation of greater numbers of spheroids suspension cultures in spinner flasks, 
gyratory rotation incubators and rotating-wall vessels are used. The main advantage of 
suspension cultures is a good diffusion; that means the spheroids are supplied with 
nutrients and by-products are removed efficiently ([29]; reviewed in [21]). 
In spinner flasks growth medium is stirred continuously by impeller mixing, this constant 
movement prevents the attachment of the cells with the walls and the bottom of the flask 
([29]; reviewed in [21]). A similar culture method uses Erlenmayer flasks containing a 
tumour cell suspension, which is then placed on a gyratory rotation incubator for spheroid 
aggregation and further growth (reviewed in [21]). 
Rotating-wall vessels are horizontally rotating vessels, which are completely filled with 
cell-suspension. Due to the constant rotation the cells never reach the bottom and cell-
surface attachment is prevented. The lack of air bubbles minimizes fluid turbulences and 
shear forces on the cells; this is an advantage especially for fragile cells ([30]; reviewed in 
[21]). 
 
Microcarrier beads 
Cells, which do not aggregate spontaneously and need attachment to form aggregates, can 
be cultured on microcarrier beads. They are manufactured carriers, which are available in 
a great variety of coatings, like collagen-coated beads; composite materials, like dextram; 
and sizes. This method is used for studying cell-cell and cell-substratum interactions. 
Usually this method is combined with rotating-wall vessel culture, which allows up to 
1000-fold greater cell densities, than possible with conventional monolayer cultures. This 
is a system with the potential for high-throughput screenings ([30]; reviewed in [21]). 
 
Scaffold based culture  
Within this method cells attach to prefabricated scaffolds, on which they can migrate, 
divide and form complex 3D structures. They consist most commonly of collagen I (see 
below) but also other ECM proteins or synthetic polymers can be used. Growth or 
regulatory factors can be supplemented. Scaffold culture models are used for long term 
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studies of growth and differentiation of epithelial cells, neurons, endothelial cells and 
fibroblasts ([31]; reviewed in [21]).  
 
Collagen gel culture 
For this methods cells are cultured in type I collagen gel, which is covered with growth 
medium. There are two different possibilities to grow cells in collagen gel, either by using 
a single-cell suspension or by spheroid culture. For single-cell suspension trypsinised 
cells are pelleted, resuspended in collagen I solution, which is thereafter induced to 
polymerize. For spheroid collagen gel culture cells are aggregated to spheroids and 
embedded into collagen gel. After polymerisation gels can be cultured attached to the 
surface or released and free-floating in growth medium [15, 32]. 
Whether using attached or free-floating collagen gels depends on the experiment itself. 
For instants T47D cells will not form differentiated structures while they are cultured in 
attached collagen gels, instead they continue to proliferate. When these collagen gels are 
released, the cells start with tubulogenesis and form structures with lumen, since they 
become mechanical unloaded which leads to collagen gel contraction and decreased 
proliferation [15]. 
 
1.2.3 Cell invasion assays 
The invasion of BM is a contributing factor in metastasis and angiogenesis in tumour 
development. BM is a specialised ECM remaining at the basolateral side of the cells [4]. 
Benign tumours do not cross the BM layer, but malign tumours do so and subsequently 
invade organs and spread over the whole organism (metastasis) [33]. For studying 
invasive potential of various cell types in-vitro different assays are used.  
 
Transwell invasion assay 
This assay is quite the same as the boyden chamber migration assay, which consists of 
two chambers filled with growth medium separated by a porous filter. Cells are seeded in 
the upper compartment and can migrate through the filter to the lower chamber, where 
they can be quantified [34]. The only difference to the invasion assay is that the porous 
filter of the upper chamber is overlaid with a layer of ECM, like collagen I or Matrigel® 
before cells are seeded. This prevents non-invasive cells from migrating to the lower 
chamber. Invasive cells, which reach the lower chamber, can be cultured for further 
experiments [35]. This assay can be expanded to a chemoinvasion assay by adding 
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growth factors like VEGF, PDGF or EGF to the lower chamber as chemoattractants to 
stimulate the cells [33, 35]. 
To differentiate between cells with a high invasive potential and slow motility and cells 
with a low invasive potential but high motility it is recommended to calculate the 
“invasive index”. Therefore an invasion assay and a migration assay have to be 
performed, evaluated and then the ratio of those two determines the invasive index [33]. 
 
Platypus invasion assay 
This invasion assay is also a modification of a migration assay. For the migration assay 
96-well plates are used which are equipped with small silicone stoppers. A cell-
suspension is added and after attachment of the cells the stoppers are removed leaving a 
round exclusion zone, in which the cells migrate. For the invasion assay the bottom of the 
96-well plate is coated with basement membrane extract (BME), which has to polymerise. 
Thereafter the silicone stoppers are fitted, cell suspension is added and the cells adhere to 
the BME. Now the stoppers are removed leaving a cell-free zone. The last step is to 
overlay the cells and the invasion zone with a thicker layer of BME. Cells start to invade 
into the middle zone, what can be documented with a microscope [36]. 
 
Spheroid collagen gel invasion assay 
Spheroids are defined as multicellular cell aggregates, which are able to mimic the in-
vivo situation of primary tumour clusters. Meaning, that cells located at the outlying area 
are proliferating, compared to cells in the innermost, which become quiescent and 
undergo apoptosis or necrosis, due to the lack of oxygen and nutrients and accumulation 
of lactate in the inner spheroid [27]. 
Multicellular spheroids can be produced by hanging drop cell cultivation, spinner flask 
culture, gyratory rotation culture, rotating-wall vessel culture and by cultivating cells in 
non-adherent 96-well plates in methylcellulose-/agar-growth medium suspension [27, 37, 
38]. 
These spheroids can thereafter be embedded into collagen I or BME gels. Tumour cell 
lines, endothelial cell lines and mesenchymal cell lines such as fibroblasts start to invade 
the surrounding gel in a “starburst” like outgrowth. This outgrowth can be followed with 
a microscope and quantified. These collagen gels can be treated with inhibitors and 
growth factors, also cells treated with siRNA can be embedded [38, 39]. By using this 
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method the requirement of cancer cells for the membrane-anchored metalloproteinase 
MT1-MMP for invasion was investigated [39]. 
In our experiments we produced multicellular spheroids using 96-well plates with a 
methylcellulose-cell suspension mixture. After 6 hours the spheroids are harvested, to 
prevent the cells from nemosis. The spheroids are then embedded in collagen I gels and a 
mesh is added to avoid collagen gel contraction, otherwise we could not be able to 
observe and quantify the outgrowth. 
 
Nested collagen matrices 
This method is akin with the spheroid collagen gels. The only difference is that the cells, 
predominantly fibroblasts, are not aggregated to multicellular spheroids. The cells are 
embedded in collagen I gel and incubated over night, so that the fibroblasts contract the 
gel to 1-2 mm diameter, which are called dermal equivalents. These are then embedded in 
the middle of fresh collagen gel. After polymerisation the cells start to invade the 
surrounding gel, this can be observed with a microscope and quantified [40]. It is used to 
study wound healing contraction and cell-matrix interactions [41]. 
 
1.2.4 3D co-culture methods 
Confrontation assay 
This assay is used for co-culture of tumour cells and stromal cells or other cell lines. This 
culture method is for example used to mimic scirrhous breast tumours. Therefore one 
fibroblast spheroid is transferred into each well of an agarose-coated 96-well plate and 
co-cultured with one tumour cell aggregate. Experiments show that co-cultures of breast 
tumour cells with normal skin fibroblasts mirror early stages during breast tumour 
development; in contrast co-cultures with tumour-derived fibroblasts reflect advanced 
scirrhouse breast tumours due to differentiation of fibroblasts to myofibroblasts [42]. 
Another possibility is to transfer one spheroid of the individual tumour cells and stromal 
cells onto a poly-D-lysine-coated cover slip where they are co-cultivated. The spheroids 
can be thereafter fixed and analysed with a microscope [43]. 
 
Artificial skin model 
This assay is used for studying interactions between tumour spheroids and fibroblasts. 
Therefore tumour spheroids were produced for instance in non-adherent 96-well plates in 
methylcellulose medium suspension. The spheroids were thereafter transferred into a 
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microcentrifuge tube; fibroblasts were trypsinised and transferred into the tube as well. 
Afterwards the spheroids and cells were agitated with collagen gel and transferred into 
casting devices for polymerisation. Further cultivation was proceeded in medium-
containing 24-well plates (Dolznig et al, submitted to American Journal of Pathology). 
 
 
1.3 mTOR pathway  
For our analysis we chose the mammalian target of rapamycin (mTOR) pathway, due to 
its involvement in many important cellular functions as regulating mRNA translation, 
ribosomal biosynthesis, proliferation, metabolism and cell size via its downstream targets 
(reviewed in [44]). Another reason is that this pathway was previously extensively 
studied using monolayer cultures of IMR-90 in our lab [45, 46]. However, mTOR 
signalling has not been studied very well in fibroblasts cultivated in 3D so far. Recently in 
synovial fibroblasts mTOR expression and their invasive properties after Rapamycin 
treatment were studied using Western blot analysis and transwell invasion assay. Reduced 
phosphorylation of mTOR, p70 S6K and 4E-BP1 was found, confirming mTOR 
inhibition. Furthermore after treatment with Rapamycin the invasiveness of the cells is 
specifically lower than in the controls [47]. In a study of human skin fibroblasts in 
collagen lattices cell cycle distribution was analysed with flow cytometry. They observed 
decreased proliferation with better biological viability [48]. 
 
1.3.1 mTOR 
mTOR is a member of the PIKK (phosphoinositide 3-kinase related kinase) family of 
protein kinases and is part of two distinct complexes called mammalian TOR complex 1 
and 2 (mTORC1/mTORC2) (reviewed in [49]). In the early 1970s the bacterial strain 
Streptomyces hygroscopicus was isolated on the island of Rapa Nui. It excreted an 
antifungal macrolide, which was then called rapamycin [50]. It was used as an 
immunosuppressant to prevent graft rejection and with its help mTOR was discovered. 
Rapamycin is a specific and potent inhibitor of mTOR, by interacting with FK506-
binding protein 12 (FKBP12) to assemble a FKBP12/rapamycin complex [51]. This 
complex interacts with the FKBP12-rapamycin binding (FRB) domain of mTOR kinase, 
causing a decrease of proliferation, mRNA translation and ribosomal biosynthesis [52]. In 
this way mTORC1 was discovered in 1994 [51, 53, 54] and mTORC2 in 2004 [55, 56].  
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1.3.2 mTORC1 and mTORC2 assembly 
mTORC1 consists of mTOR, raptor, PRAS40, Gβl/mLST8 and DEPTOR (see Figure 1.2 
A). Compared to mTORC2 it is a rapamycin-senstive complex, since rapamycin 
destabilises the connection between mTOR and raptor leading to a decrease of mTORC1 
activity. Raptor means regulatory associated protein of mTOR and is a scaffold protein, 
which connects mTORC1 downstream targets, containing the TOR signalling (TOS) 
motif, with the mTOR kinase ([53]; reviewed in [44, 49]). The proline-rich AKT substrate 
of 40 kDA (PRAS40) is a tumour suppressor protein, which interacts with raptor to 
inhibit mTORC1 activity [57]. Gβ1/mLST8 binds to the mTOR kinase domain and 
provides the assembly and the signalling of the complex [54]. DEPTOR is an inhibitor 
and can be found in both complexes like Gβ1/mLST8 ([58]; reviewed in [59]). 
mTORC2 contains besides Gβ1/mLST8 and deptor also rictor, mSin1 and PRR5/protor 
(see figure 1.2 B). The rapamycin-insensitive companion of mTOR (rictor) [55] and 
mSIN1 provide mTORC2 assembly and signalling [60], the function of PRR5/protor is 
not clear at the moment (reviewed in [44]). 
mTORC1 is directly responsible for linking environmental cues with protein synthesis, 
cell growth, cell proliferation and cell metabolism via its downstream targets. These 
functions are promoted by growth factors and nutrients ([61]; reviewed in [44, 49]. 
mTORC2 controls whole body growth, cytoskeleton, metabolism and cell survival [55, 
56, 62]. 
 
 
Figure 1.2: Scheme shows mTORC1 assembly. Its kinase activity is promoted by growth factor and 
nutrient stimulation and leads to increased cell proliferation, cell growth and protein synthesis. B 
mTORC2 assembly leads to whole body growth, cell survival and metabolism regulation. 
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1.3.3 Downstream targets of mTORC1 
The main downstream targets of mTORC1 are ribosomal S6 kinase 1 and 2 (S6K1, 
S6K2) and eukaryotic initiation factor 4 E (eIF4E) binding protein 1 (4E-BP1), all three 
components of the translation machinery (reviewed in [49]). The mTOR/raptor mediated 
phosphorylation of p70S6K1 takes place at the hydrophobic motif site threonine 389 
(T389) [63]. One substrate of p70S6K1 is among others ribosomal protein S6, which is 
phosphorylated at S240/244 and S235/236 [64]. 4E-BP1 is phosphorylated at T37/46, 
T70, S65 to inhibit its function and support its dissociation from eIF4E, which promotes 
the assembly of the eIF4E complex (eIF4F) for initiation of mRNA translation ([65]; 
reviewed in [44]). Phosphorylation of S6 and 4E-BP1 are dependent on activated 
mTORC1 signalling, meaning that translation and subsequent cell growth and 
proliferation are regulated by growth factor and nutrient stimulation ([65]; reviewed in 
[44]). 
 
Figure 1.3: S6K1 and 4E-BP1 are the main downstream targets of mTORC1. It phosphorylates S6K1 at 
T389 guiding its activation and subsequently its phosphorylation of S6 at S240/244 and S235/236. 
Inhibitory phosphorylations of 4E-BP1 by mTORC1occurs at multiple sites (T37/46, S65, T70). 4E-BP1 
inhibits eIF4E to initiate mRNA translation. 
 
1.3.4 Downstream targets of mTORC2 
One of mTORC2’s substrates is the proto-oncogene AKT. It controls metabolic 
processes, cell migration, cell survival and cell proliferation. mTORC2 directly 
phosphorylates AKT at the turn motif site T450, to stabilise newly synthesised proteins. 
In addition it is phosphorylated at S473 by mTORC2 ([66]; reviewed in [44]). For full 
AKT activation a second phosphorylation besides S473 at T308 is necessary, which is a 
target of phosphoinositide-dependent kinase 1 (PDK1), a downstream target of PI3K 
(reviewed in [44]). 
24 
 
Fully activated AKT phosphorylates tuberous sclerosis complex gene 2 (TSC2) and 
PRAS40 guiding their inhibition to increase mTORC1 activity. AKT has been 
demonstrated to phosphorylate and thereby active or inhibit multiple targets such as the 
transcription factor FOXO, the apoptosis regulator Bcl-2-associated death promoter 
(BAD) and others ([67]; reviewed in [68]). 
 
 
Figure 1.4: This figure shows mTORC2’s downstream target AKT. Newly synthesised AKT is first 
phosphorylated at T450 by mTORC2, when full activation is needed AKT is phosphorylated by 
mTORC2 at S473 and also by PDK1 at T308. AKT controls mTORC1 activity, apoptosis, cell 
metabolsim and a variety of other processes. 
 
1.3.5 Upstream regulators  
mTORC1 
The main upstream regulators of mTORC1 are the tuberous sclerosis complex genes 
TSC1 and TSC2, encoding hamartin and tuberin respectively. They form a heterodimer 
(tuberous sclerosis complex, TSC) and are classified as tumour suppressor proteins. 
TSC1/TSC2 complex suppresses mTORC1 activity by inhibiting its activator ras-
homologue enriched in brain (Rheb). TSC2 possesses a GTPase activating protein (GAP) 
activity, which converts the GTP-bound active state of Rheb into a GDP-bound inactive 
state. However the biochemical mechanism by which mTORC1 is activated via Rheb, is 
not defined yet ([69, 70]; reviewed in [44, 71]). 
TSC itself can be phosphorylated by AKT through the PI3K pathway. Therefore AKT is 
activated by PDK1 (T308) and by mTORC2 (S473). Thereafter the targeting sites S939, 
S981 and T1462 of TSC2 are phosphorylated by AKT, which leads to an activation of 
mTORC1 (see Figure 1.5) ([72]; reviewed in [44]). 
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PRAS40 is another phosphorylation substrate of AKT, which is stimulated by insulin 
through the PI3K pathway leading to the dissociation of PRAS40 from mTORC1. This 
relieves its inhibitory function and enhances mTORC1 signalling towards S6K1 and 4E-
BP1 (see figure 1.5) ([57, 73]; reviewed in [49]). 
Another activating effect of mTORC1 is mediated by the Ras/ERK pathway. It inhibits 
TSC2 through an inhibitory phosphorylation at S664 (promoted by ERK) and S1798 
(promoted by RSK) (see figure 1.5) ([74]; reviewed in [49, 75].) 
Nutrient deprivation and cellular stress like hypoxia and genotoxic stress leads to an 
elevation of AMP and of the AMP/ATP ratio, causing phosphorylation of AMP-activated 
protein kinase (AMPK) through the tumour-suppressor serine-threonine kinase 1 (LKB1). 
AMP then binds to a subunit of AMPK to prevent its dephosphorylation. Its main 
function is to activate ATP-generating pathways and to inhibit ATP-consuming functions 
like the mTOR pathway. This kinase phosphorylates TSC2 on S1345 to enhance its GAP 
activity towards Rheb-GTP, leading to mTORC1 inhibition. Another substrate of AMPK 
is raptor, which is directly phosphorylated at S792 and S722, enabling 14-3-3 binding and 
initiates its degradation. This prevents cells from energy deprivation-induced apoptosis 
(see Figure 1.5) ([69, 76]; reviewed in [44, 49]). 
 
mTORC2 
Upstream regulators of mTORC2 remain almost unknown. Probably PI3K lies upstream 
as it promotes phosphorylation of Akt (S473) via mTORC2 [68, 75] and its inhibition 
reduces mTORC2’s activity ([77]; reviewed in [44]). 
 
 
Figure 1.5: Scheme illustrating the upstream regulators of mTORC1. AKT phosphorylates TSC2 at 
S939, S981 and T1462 and activating mTORC1. AKT also phosphorylates PRAS40 resulting in 
increased mTORC1 activity. Nutrient deprivation and cellular stress activates AMPK, which inhibits 
raptor and enhances TSC2 for decreased mTORC1 activity. 
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1.3.6 Negative feedback-loop 
Activated mTORC1 leads to an inhibitory feedback loop to insulin receptor substrate 
(IRS). This is mediated by an inhibitory phosphorylation of IRS through S6K1, guiding 
its release from PI3K, that shows decreased signalling towardss AKT, TSC2 and PRAS40 
reducing mTORC1 activity (see Figure 1.6 A). Furthermore raptor itself binds the SAIN 
domain of IRS leading to its inhibition [78]. When this negative feedback loop does not 
operate properly, an excess of nutrients can lead to increased mTORC1 activity, what 
may result in insulin resistance and type II diabetes ([79]; reviewed in [44, 49]). 
In another feedback loop p70S6K1 phosphorylates rictor on T1135, which stimulates 14-
3-3 binding to rictor, resulting in a decrease in AKT S473 phosphorylation to enhance 
GAP activity of TSC2 towardss Rheb for reduced mTORC1 activity (see Figure 1.6 B) 
([80]; reviewed in [44]). 
 
 
 
Figure 1.6 A Negative feedback loop of S6K1 towardss IRS, guiding its dissociation of PI3K and 
reduction of AKT activity resulting in enhanced TSC2 and decreased mTORC1 activity. B 
Phosphorylation of rictor by S6K1 leads to decreased mTORC2 and AKT activity, stimulating TSC2 
GAP activity towardss mTORC1. 
 
1.3.7 Treatment with rapamycin 
mTORC1 is inhibited by rapamycin, which interacts with FKBP12 to assemble a 
FKBP12/rapamycin complex [51], enhancing the dissociation of raptor from mTOR and 
reduced substrate binding [81]. This results in decreased mRNA translation, smaller cell 
size and cell cycle arrest through dephosphorylation of 4E-BP1 [82], p70 S6K1 at T389 
and subsequent S6 dephosphorylation of S240/244. Concomitantly treatment with 
rapamycin activates protein phosphatase A (PP2A) leading to dephosphorylation of p70 
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S6K and 4E-BP1 [83]. This occurs already a few minutes after the application of the drug 
([46, 61, 63, 84]; reviewed in [85]). 
mTORC2 is known as the rapamycin-insensitive complex. Short-term treatment with 
rapamycin showed dephosphorylation of rictor and mSIN1 in the cytosplasma with no 
impact on mTORC2 assembly [45]. The rapamycin/FKBP12 complex cannot bind to 
mTORC2 itself, but it can compete with its components to bind newly synthesised mTOR 
to prevent the assembly of new mTORC2 complexes ([55, 56]; reviewed in [86]). 
Prolonged treatment with rapmycin leads to complete dephosphorylation of rictor and 
mSin1 and dependent on the transformation status in some cell lines like PC3 and HEK-
293T to a decrease of AKT S473 phosphorylation [87]. Diminished AKT S473 
phosphorylation does not occur after long-term treatment with 100 nM rapamycin in 
IMR-90 [45]. 
Treatment with rapamycin induces AKT activation in a dose dependent manner, due to 
the loss of the negative feedback loop, in which S6K1 normally inhibits IRS and rictor, 
respectively. Low rapamycin concentrations lead to increased AKT activation, whereas 
high concentrations inhibit its phosphorylation. ([84, 88]; reviewed in [85]). 
 
1.3.8 mTOR associated disease and cancer 
Since the mTOR pathway consists of many proto-oncogenes like AKT or Ras and 
tumour-suppressors as TSC1, TSC2 and LKB1, it is not astonishing that mutations cause 
a variety of cancers and other disease. 
Genetic inactivation of TSC1 or 2 leads to an increase of mTORC1 activity with 
augmented protein synthesis and cell growth, causing tuberous sclerosis complex (TSC) 
and other related disease. TSC is an autosmoal dominant disorder, but the majority of 
mutations occur de novo in either TSC1 or TSC2. Tuberous sclerosis is characterised by 
the formation of hamartomas in the kidneys, heart, skin and brain ([89]; reviewed in [52, 
71, 90]). 
Lymphangioleiomyomatosis (LAM) is associated with mutations in TSC2. It is 
characterised by benign lesions of smooth muscle-like cells in the lung and affects almost 
exclusively woman ([91, 92]; reviewed in [90]). 
The autosomal dominant polycystic kidney disease (ADPKD) is a result of mutations in 
the PKD1 gene, which encodes polycystin-1 and the PKD2 gene encoding polycystin-2. 
Patients suffer from renal cysts, which lead to a replacement of normal renal tissue and a 
significant overall growth of the organs ([93]; reviewed in [90]). 
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Mutations in the tumour-suppressor gene LKB1 causes Peutz-Jeghers syndrome, resulting 
in gastrointestinal hamartomatous polyps. Patients show also an increased risk of 
malignant tumours in the intestine and elsewhere ([94]; reviewed in [52, 90]). 
mTOR hyperactivation can occur in various tumours by dysfunction of various 
components of the mTOR/PI3K/ERK pathway. For instance oncogenic Ras can activate 
the mitogen-activated protein kinase (MAPK)/ERK pathway, leading to phosphorylation 
of TSC2 with following upregulation of p70S6K and 4E-BP1 (reviewed in [74, 90]). 
Another way is through the PI3K pathway, where mutations in upstream elements can 
lead to enhanced AKT signalling and inhibition of TSC2 (reviewed in [90]). 
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2 Material and methods 
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2.1 Cell culture 
2.1.1 Cells 
Normal diploid human lung fibroblasts (IMR-90, CCL-186) obtained from the American 
Type Culture Collection (ATCC) were used for this study. These primary fibroblasts were 
isolated from a 16-week old female fetus in 1975 by Nichols [12]. IMR-90 are primary 
cells, which are nontransformed and nonimmortalised displaying a limited proliferation 
capacity of 58 population-doublings before the onset of senescence [12]. The cells display 
an elongated fibroblastoid phenotype and adhere to standard plastic cell culture dishes. 
The cells were kept in DMEM high glucose (4.8 g glucose/l) supplemented with 10% 
fetal calf serum, 30 mg/l penicillin, 50 mg/l streptomycin sulphate and 2 mM l-glutamine. 
Cells used in the entire study were from passages 16-19, in order to avoid artefacts due to 
the onset of senescence. 
 
2.1.2 General issues 
All cell culture procedures were performed in laminar flow hoods (MSc Advantage 
biological safety cabinet from Thermo Scientific, Waltham, MA, USA). Furthermore all 
surfaces, gloves and instruments, like tweezers or pipettes, where wiped with 96% 
Ethanol (EtOH) periodically. 1.5 ml microcentrifuge tubes (VWR, West Chester, PA, 
USA, 211-0015 (Europe)/ 20170-038 (North America)) and pipette-tips (Starlab, 
Ahrensburg, Germany, 0,1-10 µl S1111-3000 / 1-200 µl S1111-1006 / 101-1000 µl 
S1111-2021) were sterilized in an autoclave at 121°C for 20 min. Growth medium, 1x 
PBS and TE were always prewarmed in a 37°C water bath and the outside of the flasks 
were afterwards sterilized with EtOH before use. 
Cells were cultured in 100 mm tissue culture plates (Iwaki, Asahi Glass Co LTD, Tokyo, 
Japan, 3020-100) in Heraeus BBD 6220 incubators (Thermo Scientific, Waltham, MA, 
USA) at 37°C, 5% CO2 and 80% rH (relative humidity).  
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2.1.3 Buffers and solutions 
Trypsin-EDTA solution (TE):  
- 2200 U trypsin 
- 2% Na EDTA pH 7.4 
- 1x PBS 
For TE 1g trypsin (2.2 U/mg) was dissolved in 245 ml of 1x PBS supplemented with 5 ml 
of Na EDTA (1% solution, pH 7.4); the resulting solution was mixed by agitation. 
Afterwards it was filtered with a sterile filtration unit with 0.2 µm pore size (Sarstedt, 
Nümbrecht, Germany, 83.1822.001), aliquoted in 10 ml portions and stored at -20°C. 
After thawing for use it was stored at 4°C. 
 
Antibiotics stock solution: 
- 10 g/l streptomycin sulfate 
- 6 g/l penicillin 
- 10% 10x PBS 
Antibiotics were prepared by dissolving 1 g of streptomycin sulfate and 0,6 g of penicillin 
in 10 ml of 10x PBS. H2Odest. was added to a final volume of 100 ml. After sterile 
filtration with 0.2 µm pore size 5 ml aliquots in 15 ml centrifuge tubes were stored at -
20°C. 
 
DMEM with 10% FCS: 
- DMEM high glucose (4.8 g glucose/l) 
- 10% FCS 
- 60 mg/l penicillin 
- 100 mg/l streptomycin sulfate 
- 2 mM l-gluatmine 
Growth medium was prepared by thawing of a 50 ml aliquote of fetal calf serum, of a 5 
ml aliquote of a 200 mM stock l-glutamine and of a 5 ml aliquote of antibiotics at 37°C in 
a watherbath. Afterwards the surfaces of these flasks and of a 500 ml flask of DMEM 
high glucose (4.8 g glucose/l) were wiped. In a laminar flow hood 50 ml of serum, 5 ml 
of l-glutamine and 5 ml of antibiotics was pipetted in the flask with DMEM and mixed 
gently by agitation. The concentration of fetal calf serum in DMEM was 10%, of l-
glutamine 2 mM, of penicillin 60 mg/l and of streptomycin sulfate 100 mg/l. Complete 
growth medium was stored at 4°C and was depleted within 2 weeks. ö 
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2.1.4 Trypsinisation 
When cells reached 90-95% confluency they were splitted in a ratio of about 1:3-1:4. 
Higher splitting ratios are not recommended. Growth medium was removed from a 100 
mm tissue culture plate and was rinsed with 5 ml of 1x PBS to remove residual serum 
containing growth medium that may inhibit the enzymatic activity of trypsin. For tissue 
culture plates with a diameter of 100 mm 500µl of TE was added and the dishes were 
incubated at 37°C in the incubator with periodical microscopic examination until all cells 
were detached. Thereafter 5 ml of complete growth medium (DMEM +10% serum) was 
added and cells were resuspended carefully by pipetting. Tissue culture plates were 
incubated at 37°C in the incubator.  
 
2.1.5 Cell passaging 
Cells were trypsinised as described in 2.1.4. When all cells were detached, they were 
resuspended in 8 ml of fresh growth medium and 4 new tissue culture plates were filled 
with 2 ml cells suspension each. Afterwards 8 ml growth medium was added, cells were 
resuspended carefully and equally distributed all over the plate. Thereafter the tissue 
culture plates were incubated at 37°C in the incubator. 
 
2.1.6 Cell freezing for storage 
Cells were usually frozen when they were about 75% confluence. Cells were trypsinised 
as described, resuspended with 5 ml of complete growth medium, transferred into 15 ml 
centrifuge tubes (Sarstedt, Nümbrecht, Germany, 62.554.502) and centrifuged at 1000 
rpm for 3 min. at room temperature in a centrifuge (Thermo Scientific Multifuge X3 FR). 
Thereafter the supernatant was discarded and the pellet was resuspended in 900 µl of 
fresh DMEM and slowly dropped into CryoTubes™ (Nalge Nunc International, 
Naperville, IL, USA, 343958) containing 100 µl of DMSO during very soft swaying. 
After closure the tube was inverted 3 times and immediately cooled on ice for 20 min. 
Thereafter the tube was frozen at -80°C over night in a 1 cm thick polystyrene box in 
order to reach a cooling rate of approximately 1°C/minute. Afterwards it was transferred 
into a liquid nitrogen tank at -196°C for long-term storage.  
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2.1.7 Cell thawing 
100 mm tissue plates with 10 ml of complete growth medium were prewarmed. The 
frozen cells in Cryo-Tube™ vials were taken off the liquid nitrogen tank and thawed in a 
37°C water bath right away until the last ice crystals disappeared. Afterwards the tube 
was wiped with 75% EtOH and the cells were resuspended in 10 ml fresh prewarmed 
medium and seeded into the prepared plate and incubated at 37°C in the incubator. After 
24 hours the growth medium was removed and fresh medium was added. 
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2.2 Three-dimensional collagen gel assay 
2.2.1 Buffers and Solutions 
Methylcellulose (MC): 
- 1.5% (w/v) Methylcellulose 
- DMEM supplemented with 2 mM l-glutamine 
Methylcellulose was used for cell aggregation and for the preparation of collagen gels, 
therefore it was needed to be sterile. After autoclaving only sterile DMEM was used and 
all procedures like opening the flask and adding of DMEM were done in laminar flow 
hoods.  
In a 1 l glas flask 15 g of methylcellulose was weighed, a magnetic stirrer was added and 
the not firmly closed flask was autoclaved for 20 min. at 121°C. Thereafter 500 ml of 
preheated DMEM (60°C) was filled in the flask and dissolved by stirring for 20 min. 
using the containing autoclaved magnetic stirrer afterwards. Another 500 ml DMEM with 
room temperature and 10 ml of the aliquoted 200 mM l-glutamine stock solution were 
added and stirring was continued over night at 4°C. The solution was thereafter aliquoted 
in 50 ml centrifuge tubes, centrifuged for 2 h with 5000g at room temperature. The clear 
highly viscous supernatant was transferred into fresh 50 ml centrifuge tube and the rest 
was discarded. MC was stored at -20°C. The solution had a concentration of 1.5% (w/v) 
methylcellulose and 2 mM l-glutamine. 
 
Antibiotics stock solution: 
- 10 g/l streptomycin sulfate 
- 6 g/l penicillin 
- 10% (v/v) 10x PBS 
Antibiotics were prepared by dissolving 1 g of streptomycin sulfate and 0,6 g of penicillin 
in 10 ml of 10x PBS. H2Odest. was added to a final volume of 100 ml. After sterile 
filtration with 0.2 µm pore size 5 ml aliquots in 15 ml centrifuge tubes were stored at -
20°C. 
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DMEM with 2% FCS: 
- DMEM high glucose (4.8 g glucose/l) 
- 2% FCS 
- 60 mg/l penicillin 
- 100 mg/l streptomycin sulfate 
- 2 mM l-gluatmine 
Growth medium was prepared by thawing of a 50 ml aliquote of fetal calf serum, of a 5 
ml aliquote of a 200 mM stock l-glutamine and of a 5 ml aliquote of antibiotics at 37°C in 
a watherbath. Afterwards the surfaces of these flasks and of a 500 ml flask of DMEM 
high glucose (4.8 g glucose/l) were wiped. In a laminar flow hood 1 ml of serum, 0.5 ml 
of l-glutamine and 0.5 ml of antibiotics was pipetted in the flask with DMEM and mixed 
gently by agitation. The concentration of fetal calf serum in DMEM was 2%, of l-
glutamine 2 mM, of penicillin 60 mg/l and of streptomycin sulfate 100 mg/l. Complete 
growth medium was stored at 4°C and was depleted within 2 weeks.  
 
2.2.2 Establishing a protocol for the 3D collagen gel assay with IMR-90 
The basic steps for all preliminary experiments were the same as described in chapter 
2.2.3. Only the following parameters were changed to find the best conditions: 
aggregation time, cell number per spheroids and spheroid number per gels. 
 
2.2.3 Spheroid assay  
2.2.3.1 Cell aggregation 
After cells were trypsinised as described in chapter 2.1.4, they were agitated with 5 ml of 
complete growth medium (DMEM +10% serum) and were transferred into 15 ml 
centrifuge tubes. Spheroid aggregation was accomplished by using 96-well plates 
(Sterillin, Aberbargoed, Caerphilly, UK, microtiter plate 612V96, lid 642000) with a 
defined amount of cells, for that cells were counted using a Bright-Line hemacytometer 
(Hausser Scientific, Horsham, PA, USA, 3120). 10 µl of cell suspension and 10 µl of 
trypan blue were resuspended in 500 µl microcentrifuge tubes (Eppendorf, Hamburg, 
Germany, 0030 121.023) in order to identify dead cells and to exclude them while 
counting. The mixture was then pipetted on the hemacytometer and 6 large corner and 2 
middle squares were counted with a 10x objective. One big square had a surface area of 1 
mm2 and a depth of 0,1 mm that is a volume of 0,1 mm3.  
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The cell number was calculated with following formula:  
 
2 stands for the dilution factor, 8 for the counted squares and 10.000 is the conversion 
factor from 0,1 mm3 to 1 ml. 
For easier calculation and in order to avoid an insufficient amount of methylcellulose-cell 
suspension mixture for the 96-well plates we calculated with 100 wells per plate. Each 
well was filled with 100 µl of the mixture, so for 1 plate 10 ml were required. 2 ml of 
methylcellulose (20% v/v) was filled in 50 ml centrifuge tubes. The needed amount of 
cell suspension was transferred into the tube and remaining cells were transferred in new 
100 mm tissue culture plates, which were filled to a total volume of 10 ml with complete 
growth medium (DMEM +10% serum) and were incubated at 37°C in the incubator. 
Complete growth medium was added into the 50 ml centrifuge tube to a final volume of 
10 ml and mixed well by agitation. It was filled in a v-shaped reservoir (Eppendorf, 
Hamburg, Deutschland, D5063-85) and 100 µl per well were transferred with a multi-
channel pipette. Afterwards the plates were centrifuged at 1000 rpm for 3 min., then 
incubated at 37°C for no longer than 6 hours in the incubator.  
 
2.2.3.2 Harvesting spheroids 
After 6 hours of incubation the content of the 96-well plate was pipetted with a multi-
channel pipette completely off and were transferred into v-shaped reservoirs. Afterwards 
the plate was controlled with a microscope for remaining spheroids. If more than 5% 
were remaining, 100 µl of growth medium were added in these wells and were pipetted 
off once more. For 1 collagen gel the spheroids of 2 plates were transferred into a 50 ml 
centrifuge tube. They were centrifuged at 1000 rpm, 4°C for 5 min. Afterwards growth 
medium was aspirated by pipetting leaving 1 ml of medium in the tubes; the spheroids 
were resuspended carefully and transferred into 1.5 ml microcentrifuge tubes and 
centrifuged again. Then the tubes were put on ice. 
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2.2.3.3 3D-collagen gels with spheroids 
1000 µl collagen gel: - 400 µl methylcellulose  
   - 500 µl collagen I  
   - 100 µl 10x PBS  
   - 11,5 µl 1M NaOH 
A FACS-tube (BD Falcon™, BD Biosciences, Erembodegem, Belgium, 352054) for the 
collagen gel and all ingredients except 10x PBS were cooled on ice. For a single collagen 
gel 300 µl of collagen mixture were needed. Due to the high viscosity of methylcellulose 
a second FACS-tube was prepared, it was used for comparison purpose. For that it was 
filled with as much water as methylcellulose. Then methylcellulose was transferred in the 
cooled tube by pipetting until both had the same fluid level. Next collagen I and 10x PBS 
were added.  
The supernatant of the centrifuged spheroids was removed and silicone-forms with a 
diameter of 1.5 cm and a height of 2 mm were placed into tissue plates. Now as last 
component 1 M NaOH was added and the tube was shaken thoroughly. After 15-30 min. 
the gel polymerised completely. The gel was centrifuged in a precooled centrifuge for 15 
sec. at 2000 rpm at 4°C. The air bubbles were removed carefully with a pipette-tip and 
afterwards the gel was cooled on ice again. Then 300 µl of collagen gel was carefully 
agitated with the spheroids in the microcentrifuge tube and afterwards transferred into the 
form by pipetting and was evenly distributed with the pipette-tip. A ring-shaped PET 
mesh with 120 µm mesh size (Bückmann, Mönchengladbach, Germany, PET-100/77-32) 
was added, so the fibroblasts could not shrink the gel. For proper cell invasion the gels 
were incubated for 3 min. upside down in order to prevent sinking of the to the ground, 
otherwise they would behave like cells in tissue plates.  Thereafter the plate was turned on 
the right side and incubated until the gel is polymerised. 
Afterwards a few drops of growth medium were added on top of the gels and the silicon 
forms were removed carefully. The now swimming gels were transferred with a forceps 
into a 24-well plate containing 1 ml of growth medium (DMEM +2% serum) and 
incubated at 37°C in the incubator. 
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2.2.4 3D-collagen gels with single-cell suspension 
Cells were trypsinised as described in chapter 2.1.4. When all cells were detached, 5 ml 
of complete growth medium was added, cells were agitated and transferred into 15 ml 
centrifuge tubes. Cell number was determined with a hemacytometer (see chapter 2.2.3.1) 
and the calculated amount of cell suspension for 300.000 cells was transferred into a 1.5 
ml microcentrifuge tube. The remaining cells were seeded in a new 100 mm tissue culture 
plate, growth medium (DMEM +10% serum) was added to a final volume of 10 ml and it 
was incubated at 37°C in the incubator. The microcentrifuge tube was centrifuged for 5 
min. at 1000 rpm and 4°C. The supernatant was discarded and the tube was held on ice. 
Then collagen gel was produced as described in chapter 2.2.3.3. Afterwards 300 µl of this 
gel was transferred into the prepared tube. The cells were agitated carefully by pipetting, 
due to the high viscosity air bubbles were occurring very easily. Then it was transferred 
into the silicone form. A mesh was added and the gels were incubated at 37°C in the 
incubator. When it was polymerised one drop of complete growth medium (DMEM +2% 
serum) was added on top of the gel, the silicon form was removed and the gel was 
transferred into a 24-well plate containing 1 ml of growth medium and incubated at 37°C 
in the incubator. 
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2.3 siRNA knockdowns of specific proteins 
2.3.1 Buffers and solutions 
DMEM with 10% FCS w/o antibiotics: 
- DMEM high glucose (4.8 g glucose/l) 
- 10% FCS 
- 2 mM l-gluatmine  
Growth medium was prepared by prewarming a 50 ml flask with 44.5 ml of DMEM high 
glucose (4.8 g glucose/l) and thawing of a 50 ml aliquote of fetal calf serum and of a 5 ml 
aliquote of a 200 mM stock l-glutamine at 37°C in a watherbath. Afterwards the surfaces 
of the flasks were sterilised with EtOH. In a laminar flow hood 5 ml of serum and 0.5 ml 
of l-glutamine was pipetted in the flask with DMEM and mixed gently by agitation. The 
concentration of fetal calf serum in DMEM was 10% and of l-glutamine 2 mM. Growth 
medium was stored at 4°C and was depleted within 2 weeks.  
 
2.3.2 Cell preparation 
24 hours before transfection cells were trypsinised as described in chapter 2.1.4. When all 
cells were detached, they were resuspended with 5 ml of growth medium (DMEM +10% 
serum) and transferred into 15 ml centrifuge tubes. Thereafter 10 µl of cell suspension 
was mixed with 10 µl of trypan blue and cells were counted as described in chapter 
2.2.3.1 in a hemacytometer. Then 150.000 cells were seeded in each well of a 6-well plate 
(PAA, Pasching, Austria, PAA30006X). Growth medium without antibiotics was added 
to a final volume of 2 ml. The plate was incubated over night at 37°C in the incubator. 
 
2.3.3 Preparation of siRNA stock solutions 
The tube containing siRNA was briefly centrifuged to collect the content at the bottom. 
Then 200 µl of 5x siRNA buffer was diluted with 800 µl of DEPC treated water to 1x 
siRNA buffer. In a vial with 5 nmol siRNA 250 µl of 1x siRNA buffer was added in order 
to get a 20 µM stock solution. The vial was mixed thoroughly and placed on an orbital 
shaker (Rocky® 3D) for 30 min. Afterwards it was centrifuged briefly. The stock solution 
was aliquoted into volumes of 10 µl in 500 µl microcentrifuge tubes so that the siRNA 
vials were not thawed too many times and were stored at -20°C. 
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2.3.4 Transfection 
At first aliquoted OptiMEM I was prewarmed in a 37°C water bath and wiped before use. 
Then for each single well 245 µl of OptiMEM I was transferred into a 1.5 ml 
microcentrifuge tube and 5 µl of the 20 µM siRNA-stock solution was added and mixed 
gently by snapping. Lipofectamine RNAiMAX was mixed and centrifuged briefly. For 
each transfection 247.5 µl of OptiMEM I was preplaced in a microcentrifuge tube and  
2.5 µl of RNAiMax was added. The tube was inverted 3 times. For more than one 
transfection at a time a bulk solution of Lipofectamine RNAiMAX was prepared. After   
5 min. of incubation at room temperature, 250 µl of OptiMEM I-RNAiMAX solution was 
transferred in one of the prepared siRNA containing microcentrifuge tube. The tube was 
mixed gently, centrifuged briefly and incubated for 20 min. at room temperature, in order 
to form siRNA-lipidcomplexes.  
In the meantime 500 µl of DMEM was removed from each well of the 6-well plate. After 
incubation 500 µl of siRNA-lipidcomplex solution was added to the wells, mixed gently 
by pipetting and incubated for 72 hours at 37°C in the incubator. Each well contains now 
50 nM siRNA and 0.125% Lipofectamine RNAiMAX.  
 
2.3.5 Preparation of cells for 3D-collagen gels 
After 72 hours of incubation the growth medium was removed from the 6-well plates, the 
cells were rinsed with 2 ml of 1x PBS and 200 µl of TE was added. After incubation at 
37°C, when all cells were detached, the cells were agitated with 1 ml of complete growth 
medium (DMEM +10% serum w/o antibiotics) and transferred in a 60 mm tissue plate. 3 
ml of growth medium was added; cells were spread and incubated for additional 24 hours. 
The cells were then trypsinised for aggregation (see chapter 2.2.3.1). 
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2.4 Western blot analysis 
2.4.1 Buffers and solutions 
NP40 lysis buffer: 
- 40 mM Hepes pH 7.5  
- 120 mM NaCL 
- 1 mM EDTA pH 8.0  
- 10 mM 2-glycerophospate  
- 50 mM NaF   
- 0.5mM Na3VO4 
- 1% NP40  
In a 15 ml centrifuge tube 0.4 ml of 1 M Hepes (pH 7.5), 1.2 ml of 1 M NaCl, 20 µl of 0.5 
M EDTA (pH 8.0), 1 ml of 0.1 M 2-glycerophosphate, 1 ml of 0.5 M NaF, 0.1 ml of 50 
mM Na3VO4 and 1 ml of 10% NP40 were added. The solution was filled to a total 
volume of 10 ml with H2Odest.. It was mixed by agitation, aliquoted in 490 µl portions and 
stored at -20°C. 
 
PIM: 
- 2 µg/ml Leupeptin  
- 2 µg/ml Aprotinin 
- 0,3 µg/ml Benzamidine chloride 
- 10µg/ml Trypsin inhibitor 
In a 50 ml centrifuge tube 100 µg of leupeptin, 100 µg of aprotinin, 15 µg of benzamidine 
chloride and 500 µg of trypsin inhibitor was weighed and filled with H2Odest. to a total 
volume of 50 ml. The tube was mixed thoroughly by agitation, aliqouted in 10 µl portions 
and stored at -20°C. 
 
4x protein sample buffer: 
- 200 mM Tris pH 6.8  
- 400 mM DTT 
- 8% SDS    
- 0.4% Bromphenol blue 
- 40% Glycerol 
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In a 50 ml centrifuge tube 5 ml of 2 M Tris (pH 6.8), 20 ml of 1 M DTT and 20 ml of 
glycerol were added by pipetting and 4 g of SDS and 2 g of bromophenolblue were 
weighed. The tube was mixed by agitating, H2Odest. was added to a total amount of 50 ml 
and aliquots of 1 ml were prepared. They were stored at -20°C. 
 
Buffer B pH 8.8: 
- 1.5 M Tris pH 8.8 
- 0.4% (v/v) SDS 
In a 500 ml glass beaker 90.75 g of Tris was weighed and 20 ml of 10% SDS was added 
by pipetting. It was filled with H2Odest. to a volume of 250 ml. While stirring with a 
magnetic stirrer 37% HCl was added till a pH of 8.8 was achieved and the solution had 
room temperature. Thereafter it was filled with H2Odest. to a total volume of 500 ml. This 
solution was stored at 4°C. 
 
APS: 
- 10% (w/v) APS  
In a 15 ml centrifuge tube 1 g of ammonium persulfate was dissolved in 10 ml of H2Odest.. 
It was stored at 4°C. 
 
Buffer C pH 6.8: 
- 0.5 M Tris pH 6.8 
- 0.4% (v/v) SDS 
In a 500 ml glass beaker 30.25 g of Tris was weighed and 20 ml of 10% (w/v) SDS was 
added by pipetting. It was filled with H2Odest. to a volume of 250 ml. While stirring with a 
magnetic stirrer 37% HCl was added till a pH of 6.8 was achieved and the solution had 
room temperature. Thereafter it was filled with H2Odest. to a total volume of 500 ml. This 
solution was stored at 4°C. 
 
10x electrophoresis buffer: 
- 250 mM Tris   
- 1.94 M glycine 
- 1% (w/v) SDS  
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In a 1 l glass flask 30.3 g of Tris, 146 g glycine and 10 g SDS was weighed, H2Odest. was 
added to a final volume of 1 l and the buffer was stirred with a magnetic stirrer. It was 
stored at room temperature. 
 
1x electrophoresis buffer: 
- 10% (v/v) 10x electrophoresis buffer 
In a measuring cylinder 450 ml of H2Odest. were filled and 50 ml of 10x electrophoresis 
buffer were added. The cylinder was closed with parafilm and agitated well. 
 
Harlow 1: 
- 48 mM Tris  
- 386 mM glycine 
- 0,1% (w/v) SDS 
- 20% (v/v) methanol 
In a 5 l glass flask 29 g of Tris, 145 g of glycine and 5 g of SDS was weighed and filled 
with H2Odest. to a volume of 4 l. Thereafter 1 l of methanol was added and mixed by 
stirring with a magnetic stirrer. This buffer was stored at 4°C 
 
10x Ponceau S: 
- 2% (w/v) Ponceau S 
- 30% (w/v) trichlor acetic acid 
- 30% (w/v) sulfosalicylic acid 
In a 100 ml flask 2 g of Ponceau S, 30 g of trichlor acetic acid and 30 g of sulfosalicylic 
acid was weighed and filled with H2Odest. to a volume of 100 ml. The solution was mixed 
by stirring with a magnetic stirrer and was stored at room temperature. 
 
1x Ponceau S: 
- 10% (v/v) 10x Ponceau S 
In a 50 ml centrifuge tube 5 ml of 10x Ponceau S was added to 45 ml of H2Odest.. The 
solution was mixed by agitation and stored at room temperature. 
 
10x TBS: 
- 1.5 M NaCL    
- 0.5 M Tris pH 7.4 
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In a 2 l glass beaker 175.32 g of NaCl and 121.14 g of Tris was weighed and filled with 
H2Odest. to a volume of 1 l, a magnetic stirrer was added. Thereafter the pH was adjusted 
with 37% HCl while stirring and occasional cooling phases until the solution had room 
temperature and a pH of 7.4. H2Odest. was added to a total volume of 2 l and the solution 
was transferred into a 2 l glass flask by decanting. It was stored at room temperature. 
 
1x TBS-T: 
- 10% (v/v) 10x TBS 
- 0.1% (v/v) Triton X-100 
A 1 l glass flask was filled with 900 ml of H2Odest., 100 ml of 10x TBS and a magnetic 
stirrer were added. While stirring 1 ml of Triton X-100 was added and stirring was 
continued until it was mixed well. This solution was stored at room temperature. 
 
5% blocking solution: 
- 5% (w/v) milk powder 
- 1x TBS-T 
In a 15 ml centrifuge tube 10 ml of 1x TBS-T was pipetted and 0.5 g of milk powder was 
added. The tube was agitated until it was dissolved completely. This solution was never 
stored.  
 
TBS-T, 5% BSA: 
- 5% (w/v) bovine serum albumine 
- 1x TBS-T 
In a 15 ml centrifuge tube 10 ml of 1x TBS-T was pipetted and 0.5 g of bovine serum 
albumin was added. The tube was agitated until BSA was completely dissolved. It was 
stored at 4°C. 
 
stripping buffer: 
- 60 mM Tris pH 6.7 
- 2% SDS 
- 0.7% 2-mercaptoethanol 
In a 250 ml glass flask 9 ml of Tris (pH 6.7) and 30 ml of 10% SDS was added and filled 
with H2Odest. to a volume of 150 ml. Under a fume hood 1 ml of 2-mercaptoethanol was 
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added and mixed by agitation. Stripping buffer was stored at room temperature but not 
longer than over night. 
 
2.4.2 Proteinextraction 
All further steps were proceeded on ice. Growth medium was discarded and cells were 
rinsed with 5 ml of cold 1x PBS. After aspiration of 1x PBS cells were trypsinised with 
500µl of TE. Tissue culture plates were incubated at room temperature with periodical 
microscopic examination until all cells were detached. Cells were agitated with 5 ml of 
cold complete growth medium (DMEM +10% serum) and were transferred into 15 ml 
centrifuge tubes. After centrifugation with 1000 rpm at 4°C for 10 min. the supernatant 
was discarded; cells were resuspended with 1 ml of cold 1x PBS by pipetting and 
transferred into microcentrifuge tubes. After new centrifugation step the supernatant was 
removed and the cells were washed once more with 1x PBS. The tube was centrifuged 
again. In the meantime the lysis buffer was prepared. To 490µl of NP40 lysis buffer 5µl 
of PMSF and 5µl of PIM were added. Depending on the remaining pellet size after the 
last centrifugation, the double amount of NP40 lysis buffer was added, cells were agitated 
thoroughly and vortexed before the tube was incubated on ice for 20 min. in a Eppendorf 
Centrifuge 5417R (Eppendorf, Hamburg, Germany). Thereafter the tube was centrifuged 
for 20 min. at 4°C with 15.000 rpm. The supernatant was carefully transferred into new 
microcentrifuge tubes and were stored at -80°C.  
 
2.4.3 Protein preparation 
The protein amount in the extracts was measured with Bradford solution, which was 
prepared by adding 10 ml of Biorad Protein Assay to 40 ml of H2Odest.. To 500 µl of 
Bradford solution 1 µl of the protein sample and NP40 lysis buffer as a reference probe 
respectively was added in a cuvette (Sarstedt, Nümbrecht, Germany, 67.746), mixed 
gently by carefully pipetting and incubated for 5 min. at room temperature. The protein 
amount was measured with a BioPhotometer (Eppendorf, Hamburg, Germany). Then the 
amounts for 15 µg of protein samples were calculated.  
The according amounts were pipetted in new centrifuge tubes and filled with NP40-lysis 
buffer to a volume of 6 µl. 1.5 µl of 4x protein sample buffer was added, the tubes were 
vortexed, spinned and boiled at 95°C with a thermomixer (Thermomixer comfort, 
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Eppendorf, Hamburg, Germany) for 5 min. Afterwards the samples were cooled down to 
room temperature. 
 
2.4.4 SDS-PAGE 
In a measuring cylinder 1x electrophoresis buffer was prepared by adding 50 ml of 10x 
electrophoresis buffer to 450 ml of H2Odest. and it was closed with a piece of Parafilm 
“M”® (American National Can Company, VWR, West Chester, Pa, USA, 52858-032). 
Afterwards the cylinder was inverted three times and cooled down to 4°C. 
For SDS-PAGE the Mini-PROTEAN Tetra Electrophoresis System from BioRad 
(Hercules, CA, USA, 165-8002) was used, with a 15-slots comb (BioRad, Hercules, CA, 
USA, 165-3355). 
The 0.75 mm spacer plate and a short plate were combined in a casting frame, which was 
afterwards fastened in a casting stand, so that the gel could not trickle out. Thereafter the 
acrylamide gel was produced with following amounts of reagents: 
 
10.5% separating gel     stacking gel 
acrylamide   4.2 ml     acrylamide   0.5 ml 
buffer B  3 ml     buffer C  0.75 ml 
H2Odest.  4.8 ml     H2Odest.  1.75 ml 
APS   60 µl     APS   30 µl 
TEMED  5 µl     TEMED  2.5 µl 
 
At first the separating gel was produced. For that acrylamide, buffer B and H2Odest. were 
pipetted in a 15 ml centrifuge tube, APS and TEMED were added to start polymerisation 
and the centrifuge tube was mixed thoroughly. Then it was filled between the spacer and 
short plate by pipetting. To get a smooth edge 1 ml of isopropyl alcohol was added on top 
of the separating gel. After polymerisation it was poured off, washed three times with 
H2Odest. and dried with filter paper. Then the stacking gel containing acrylamide, buffer C, 
H2Odest., APS and TEMED was prepared, mixed thoroughly and pipetted on top of the 
separating gel. A 15-slot comb was added.  
After polymerisation the electrophoresis system was built with either two gels or one with 
a buffer dam. The chamber was filled with the prepared 1x electrophoresis buffer. 
Thereafter the comb was carefully removed in order not to damage the gel. The slots were 
cleaned by pipetting electrophoresis buffer in the slots.  
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The slots were loaded with 2.5 µl of PageRuler Prestained Protein Ladder and 7.5 µl of 
sample respectively by pipetting. The equipment was run with 60 V at the beginning, 
when the samples form a straight line the voltage was raised to 110 V, till the marker 
front reaches the bottom of the gel. 
 
2.4.5 Western blot 
Preliminary a 8.5 x 6 cm piece of nitrocellulose membrane (Watman, Dassel, Germany, 
10401396) was cut. To ensure proper protein transfer the membrane was equilibrated in 
Harlow buffer for 10 min. We used a Mini Trans-Blot Module (BioRad, Hercules, CA, 
USA, 170-3935) with the lower buffer tank and the lid from the Mini-PROTEAN Tetra 
Electrophoresis System for the transfer. Afterwards 2 foam pads, 4 pieces of 3MM Chr 
sheets (Whatman, Dassel, Germany, 3030 917) with a size of 8 x 10 cm, the lower buffer 
tank, inserts, a cooling unit and a lid were prepared. When SDS-PAGE was finished the 
sandwich for the western blot was assembled as follows, all foam pads and 3MM Chr 
sheets were soaked with Harlow buffer before use: on top of the black side of the insert 
one foam pad was placed and one Chr sheet was added. The SDS-PAGE gel was taken 
out of the chamber and the glass plates were parted so that the gel stayed on the short 
plate. The stacking gel was removed, one filter paper was layed on the gel, which was 
transferred on the Chr sheet and thereafter laid on the previous Chr sheet on the insert. 
The nitrocellulose membrane was put on top of it, thereafter 2 Chr sheets and the second 
foam pad. The insert was closed, put in the chamber, the cooling unit was added and 
afterwards Harlow buffer was filled to the top of the chamber. The chamber was closed 
with the lid and the equipment was run for 1 hour at 350 mA or over night at 25 mA. 
Afterwards the membrane was transferred in a box with H2Odest., which was placed on an 
orbital shaker for 5 min. to wash Harlow buffer residues away. The membrane was then 
incubated for 15 min in a box with 10 ml of Ponceau S to stain all proteins on the 
membrane; the box was put on a rocking platform (VWR, West Chester, Pa, USA, 
40000300). To destain the membrane it was swayed in fresh H2Odest. untill all lanes were 
visible and the background was white again. It was scanned and saved. Afterwards it was 
destained completely in 1x TBS-T and blocked for 1 hour in 10 ml of 5% blocking 
solution at room temperature or over night at 4°C. The membrane was then washed three 
times for 10 min. in 1xTBS-T. 
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2.4.6 Protein detection 
The blot was incubated in first antibody diluted in TBS-T, 5% BSA over night. The 
various dilution factors for the used antibodies were shown in chapter 2.4.8.1. Next day it 
was washed three times for 10 min. with 1x TBS-T. Then it was incubated in 10 ml of 5% 
blocking solution containing secondary antibody with a dilution of 1:10.000 for 1 hour at 
room temperature. After that the blot was washed three times for 10 min. with 1x TBS-T 
again. The signals were detected using enhanced chemiluminescence, which was prepared 
by mixing equal amounts of detection reagent 1 and 2. For membranes with more than 7 
lanes 1.5 ml, membranes with 4 to 7 lanes 1 ml and membranes with less than 4 lanes 0.5 
ml per reagent were used. The membrane was incubated for 1 min. with ECL, thereafter it 
was drained on paper towels and wrapped in cling film. The membrane was taped into 
cassettes and incubated with light-sensitive Amersham Hyperfilms (GE Healthcare, 
Buckinghamshire, UK, 28906837) and CL-XPosure films (Thermo Scientific, Rockford, 
IL, USA, 34089). Afterwards the films were fixed and developed using an Kodak 
Medical X-ray Processor MXP 2000 (Kodak, Carestream Health Inc, Rochester, NY, 
USA).  
 
2.4.7 Reprobing 
After detection of phosphorylated proteins the membrane was stripped to detect the 
amount of total protein. A watherbath shaker (Julabo SW22), containing a box with 
stripping buffer, was preheated to 55°C. After washing the membrane in 1x TBS-T it was 
incubated in 75 ml of stripping buffer at 55°C. For intense signals of phosphorylated 
protein the blot was incubated for 15 min., when the signal was weak the incubation time 
was shortened to 10 min.  Afterwards it was washed three times in 1x TBS-T for 10 min. 
and incubated for 1 hour at room temperature in 10 ml of blocking solution. The detection 
procedure was repeated with the primary antibodies for the total protein.  
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2.4.8 Antibodies 
The following antibodies were used for Western blot detection. 
2.4.8.1 Primary antibodies 
antibody phosphorylation source MW dilution company Lot No. 
α-Rictor - rabbit 200 kDa 1:2000 
Bethyl 
Laboratories, 
Inc. 
A300-
459A 
α-Raptor - rabbit 150 kDa 1:2000 
Bethyl 
Laboratories, 
Inc. 
A300-
506A 
α-p70 
S6K 
(108D2) 
threonine 389 rabbit 70 kDa 85 kDa 1:1000 Cell signaling #9234 
α-p70 
S6K - rabbit 
70 kDa 
85 kDa 1:1000 Cell signaling #9202 
α-pAkt 
(D9E) serine 473 rabbit 60 kDa 1:1000 Cell signaling #4060 
α-Akt - rabbit 60 kDa 1:1000 Cell signaling #9272 
 
2.4.8.2 Secondary antibody 
This secondary antibody was conjugated to horseradish peroxidase. 
antibody source dilution company Lot No. 
Goat-α-rabbit  
IgG-h+l goat 1:10.000 Bethyl Laboratories, Inc. A120-101P 
 
2.4.9 Densitometric evaluation of X-ray films 
After Western blot analysis the developed films were scanned and used for density 
measurements with ImageJ64 (version 1.64q). The image of the blot was opened and the 
colour was inverted, thereafter a square was drawn, which had the size of the biggest 
signal. It was moved to the first sample for measuring the mean intensity; then moved to a 
free space beneath the signal where the measurement was repeated to get a value for the 
background. After collecting values for all samples they were copied to Microsoft Excel 
2008, where the background was subtracted. Thereafter the intensities were normalised to 
the control for equal loading to get results, which are directly comparable. The control 
sample of each antibody was set to 100% and the corresponding percentages of all other 
samples were calculated. These data sets were presented graphically using GraphPad 
Prism 4 (GraphPad Software Inc.). 
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2.5 Flow cytometry 
2.5.1 Buffers and solutions 
collagenase B:  
- 0,10 g/l CaCl2  
- 0,10 g/l MgCl2 hexahydrate 
- 0,20 g/l KCl 
- 1x PBS w/o Ca2+, Mg2+, K  
In a 500 ml flask of 1x PBS (w/o Ca2+, Mg2+, K) 0,068 g CaCl2 dihydrate, 0,05 g MgCl2 
hexahydrate and 0,1 g KCl were weighed and mixed by stirring with a magnetic stirrer. 
An aliquot of 10 ml was sterile filtrated with a single-use syringe (B Braun, Bethlehem, 
PA, USA, 460 6051 V) and a syringe filter with 0,2 µm pore size (Whatman, Dassel, 
Germany, 6809-2122). 
 
RNAse A stock solution: 
- 20 mg/ml RNAse A 
In a 50 ml centrifuge tube 400 mg of ribonuclease A was weighed, filled with H2Odest. to a 
total volume of 20 ml and was put in a preheated thermomixer with 99°C for 5 min. 
Afterwards it was aliquoted in 1.25 ml portions, which were stored at -20°C. 
 
PI: 
- 1.176 mg/ml of trisodiumcitrat 
- 0.25 mg/ml of RNAse A  
- 0.05 mg/ml of propidium iodide 
- 0.1% Triton X-100   
In a 250 ml glass beaker 117.6 mg of trisodiumcitrate and 5 mg of propidium iodid were 
weighed and 98,75 ml of H2Odest. was added. While 1.25 ml of 20 mg/ml stock solution of 
RNAse A and 100 µl of Triton X-100 were added by pipetting the solution was mixed by 
stirring with a magnetic stirrer. When the solution was mixed thoroughly it was aliquoted 
in 5 ml and 10 ml aliquots and stored at -20°C. The solutions were not thawed more than 
twice. 
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2.5.2 Cell fixation and staining of tissue culture cells 
All further steps were proceeded on ice. Growth medium was discarded, cells were rinsed 
with 5 ml of cold 1x PBS and were trypsinised with 500 µl of TE. Tissue culture plates 
were incubated at room temperature with periodical microscopic examination until all 
cells were detached. Cells were agitated with 5 ml of cold complete growth medium 
(DMEM +10% serum) and were transferred into 15 ml centrifuge tubes. After 
centrifugation at 1000 rpm for 5 min. at 4°C the supernatant was aspirated and the cells 
were washed three times with 3 ml of cold 1x PBS. After new centrifugation step 
supernatant was removed completely. Cells were fixed in 60% ethanol, therefore cells 
were resuspended with 800 µl of cold 1x PBS by vortexing. During vortexing 1200 µl of 
absolute ethanol (-20°C) was slowly dropped into the centrifuge tube and afterwards 
vortexing was continued for additional 15 seconds. Cells were fixed over night at -20°C. 
The next day it was centrifuged at 1000 rpm for 10 min., the supernatant was discarded 
and the cell-pellet was air-dried. Then 500 µL PI was added, cells were agitated and 
incubated for 20 min. on ice in the dark. Afterwards the cell suspension was transferred 
into a FACS-tube. 
 
2.5.3 Establishing a harvesting protocol for 3D collagen gels  
Cells were trypsinised as described in chapter 2.5.2. After the last washing step with 1x 
PBS cells were centrifuged at 1000 rpm for 5 min. at 4°C. Thereafter half of the cells 
were resuspended in 150 µl of 1,25 µg/µl collagenase B dissolved in 1x PBS with 0,1 g/l 
CaCl2, 0,1 g/l MgCl2 and 0,2 g/l KCl, the second half was incubated with 150µl of the 
same 1x PBS and both were incubated for 60 min. at 37°C in the incubator. Afterwards 
1.5 µl of 0.5 M EDTA was added to stop the enzymatic activity of collagenase B, cells 
were centrifuged, supernatant was discarded and cells were resuspended in 100 µl of cold 
1x PBS. Cells were fixed in 60% ethanol, for that cells were resuspended with 800 µl of 
cold 1x PBS by vortexing. During vortexing 1200 µl of absolute ethanol (-20°C) was 
slowly dropped into the centrifuge tube and afterwards vortexing was continued for 
additional 15 seconds. Cells were fixed over night at -20°C. The next day it was 
centrifuged at 1000 rpm for 10 min., the supernatant was discarded and the cell-pellet was 
air-dried. Then 500 µL PI was added, cells were agitated and incubated for 20 min. on ice 
in the dark. Afterwards the cell suspension was transferred into a FACS-tube. 
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2.5.4 Harvesting cells from 3D collagen gels 
For FACS analysis single-cell suspension assay and spheroid assay was performed, 
respectively. 
The collagen gel is lysed with collagenase B, which is dissolved in 1x PBS with 0,1 g/l 
CaCl2, 0,1 g/l MgCl2 and 0,2 g/l KCl.  
The growth medium in the 24-well plate was discarded and the gel was washed with    
250 µl of 1x PBS twice for 10 min. After discarding 1x PBS 150 µl of 1,25 µg/µl 
collagenase B was added and the gel was incubated at 37°C in the incubator until the gel 
was solubilised and the aggregates and cells were detached. After stopping the enzymatic 
activity with 1.5 µl of 0,5 M EDTA and transferring the suspension into a vial, it was 
centrifuged at 1000 rpm for 3 min. The supernatant was discarded, 50 µL of TE was 
added and the vial was incubated at 37°C until all cells were spread. Then 1 ml of full 
growth medium (DMEM +10% serum) was added and the vial was centrifuged at 1000 
rpm for 5 min.  
 
2.5.5 Analysis 
The samples were measured with a FACSCalibur (Beckton Dickinson, Franklin Lakes, 
NJ, USA) using Cellquest (Version 6.0 BD Immunocytometry Systems) to acquire the 
raw data. FlowJo (Version 7.5.5) was used for analysis.  
Due to the treatments with collagenase B cells got sticky. For that reason the crude data 
contains many cell aggregates. For doublet-discrimination we gated our cells in a two-
dimensional dot-plot containing DNA content (FL2-A) and cell width (FL2-W). All cells 
in the quadrant from 0 - 400 were used for further size and cell cycle analysis.  
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2.6 Microscopic analysis 
2.6.1 Buffers and solutions 
4% Paraformaldehyde (PFA) pH 7.4: 
- 4% (w/v) PFA     
- 1% 1M NaOH    
- 10% 10x PBS    
In a 500 ml glass beaker 20 g of Paraformaldehyde was weighed, 250 ml of H2Odest. and 5 
ml of NaOH was added. It was stirred at 65°C untill PFA was dissolved completely. 
Thereafter 50 ml of 10x PBS was added and pH of 7.4 was adjusted. The solution was 
filled to a total volume of 500 ml with H2Odest.. It was aliquoted in portions of 10 ml and 
stored at -20°C. 
 
1x TBS-Tween: 
- 0.5% Tween-20 
- 1x TBS 
In a 250 ml glass beaker 25 ml of 10x TBS was pipetted to 225 ml of H2Odest. and was 
mixed by agitation. A magnetic stirrer was added and while stirring 1.25 ml of Tween 20 
was added by pipetting. The solution was filtered with sterile filtration units with 0.2 µm 
pore size and was stored at 4°C.  
 
1x PBS-Tween: 
- 0.5% Tween-20  
- 1x PBS 
In a 500 ml flask of 1x PBS 2.5 ml of Tween 20 was added while stirring with a magnetic 
stirrer. Afterwards it was filtered with sterile filtration units with 0.2 µm pore size and 
was stored at 4°C. 
 
Blocking buffer: 
- 5% FCS 
- 0.3% Triton X-100 
- 1x PBS  
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In a 50 ml centrifuge tube 23.5 ml of 1x PBS was preplaced by pipetting. While stirring 
with a magnetic stirrer 1.25 ml of FCS and 75 µl of Triton X-100 was added. The solution 
was stored at 4°C. 
Antibody Dilution Buffer: 
- 1% BSA   
- 0,3% Triton X-100 
- 1x PBS 
In a 50 ml centrifuge tube 40 ml of 1x PBS was preplaced and 0.4 g BSA was added. It 
was dissolved by agitation and afterwards 120 µl of Triton X-100 was added while 
stirring with a magnetic stirrer. The solution was stored at 4°C. 
 
2.6.2 Immunofluorescence stainings 
Cells were trypsinised as described in chapter 2.2.3. Then 10 µl of cell suspension was 
agitated with 10 µl of trypan blue and cell number was determined with a hemacytometer 
(see chapter 2.2.3.1). The amount of cell suspension for 75.000 cells was transferred into 
each well of a 4-well chamber slide (Lab-Tek®, Nalge Nunc International, Naperville, IL, 
USA, 177437) and complete growth medium (DMEM +10% serum) was added to a final 
volume of 1 ml. Slides were incubated at 37°C in the incubator at least over night. During 
incubation cells were treated as desired. 
After previous treatment growth medium was discarded and 500 µl of 4% PFA was added 
and incubated at room temperature for 15 min. Afterwards 4% PFA was discarded, 1 ml 
1x PBS was added and the chamber slide was closed tightly with parafilm. At this point 
the chamber slides could be stored at 4°C for weeks. 
Next step was rinsing the cells twice with 1 ml of 1x TBS-Tween for 10 min. each, then 
twice in 1x PBS-Tween for 10 min. and afterwards blocked in 30 µl of blocking buffer 
per well for 1 hour at room temperature. Then the wells were washed three times for 10 
min. with 1 ml of 1x PBS-Tween again. The chambers and the adhesive were carefully 
removed. From now on all washing and incubation steps were performed in a humid 
chamber. 30 µl/well of primary antibody in antibody dilution buffer was added and 
incubated over night at 4°C. For double labelling both primary antibodies were diluted in 
the same tube with antibody dilution buffer. For the used primary antibodies and dilution 
factors see chapter 2.6.6.  
Next day cells were rinsed three times with 1ml of 1x PBS-Tween for 5 min. Cells were 
incubated with 30 µl/well of secondary antibody (dilution factor 1:500) in antibody 
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dilution buffer for two hours at room temperature in the dark. For double labelling both 
secondary antibodies were diluted in the same tube with antibody dilution buffer. 
Afterwards slides were washed with 1 ml of 1x PBS-Tween three times for 5 min., 50 
µl/well of 2 µg/ml DAPI with 0,6µl of Alexa Fluor® 546 phalloidin (dilution factor 1:80) 
was added and chamber slides were incubated for 45 min. at room temperature in the 
dark. 
At last cells were rinsed with 1 ml of 1x PBS-Tween, mounting medium was dropped on 
the slides and cover slides were added. They were stored at 4°C and protected from light. 
 
2.6.3 Immunoflourescence stainings of collagen gels 
For microscopic analysis the spheroid assay was performed with 1,500 cells per spheroid. 
The basic steps of this protocol were the same as described in chapter 2.6.2 only the 
following parameter were changed. 
After removing growth medium the collagen gels were fixed with 1 ml 4% PFA for 30 
min. at room temperature in the same 24-well plates they were incubated with. Like 
chamber slides the collagen gel could be stored with 1 ml 1x PBS. 
After washing steps the gels were blocked for 1½ hour with 30 µl of blocking buffer at 
room temperature. The following washing steps were the same as above. A piece of 
parafilm was placed in a humid chamber and drops of 1x PBS-Tween were preplaced. 
Then the gel was cut into pieces, containing parts of the mesh and each one was laid 
down on a drop, so that the gel unwinds.  
After the last washing step, for each gel fragment a drop of mounting media was 
preplaced on a glass slide (Thermo Scientific, Waltham, MA, USA, DXD-10143560) and 
the parts were transferred. Then a cover slide (Thermo Scientific, Waltham, MA, USA, 
DXD-10143263 24x60 mm #1) was added and the slides were stored at 4°C, protected 
from light. 
 
2.6.4 Microscopic analysis 
2.6.4.1 Light microscopic analysis 
We used an Olympus IX51 microscope with the camera XC50 and CellF for image 
capturing. Invasion area of spheroids in collagen gels was measured using the software 
CellD. All invasive cells outside the spheroid were surrounded with the function “closed 
polygon”. After a complete turn the spheroid size itself was measured, these two results 
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were subtracted. Examined spheroid pictures were saved as new 8-bit files with scale 
bars, the calculated size was used for further analysis in GraphPad Prism 4 and Microsoft 
Excel 2008 (see chapter 2.8). 
2.6.4.2 Confocal microscopic analysis 
All samples were analysed on a Zeiss LSM5 Exciter confocal microscope (Carl Zeiss, 
Oberkochen, Germany).  
For the analysis of cleaved caspase-3 stained collagen gels, five optical sections through 
randomly chosen spheroids were captured, which were then merged to one picture using 
the projection tool of ImageJ64. Within the spheroids condensed nuclei could be 
observed. Cleaved caspase-3 positive cells, normal shaped nuclei and condensed nuclei 
were thereafter counted with the cell counter tool. These results were analysed using 
Microsoft Excel 2008 and GraphPad Prism 4 (see chapter 2.8).  
 
2.6.5 Antibodies 
2.6.5.1 primary antibodies 
 
antibody phosphorylation source dilution company Cat No. 
α-pS6  serine 240/244 rabbit 1:100 Cell Signaling #2215 
α-pAKT (D9E) serine 473 rabbit 1:200 Cell Signaling #4060 
α-mTOR - rabbit 1:200 Cell Signaling #2972 
α-AKT - rabbit 1:200 Cell Signaling #9272 
α-4E-BP1 - rabbit 1:200 Cell Signaling #9452 
α-p-H3 serine 10 rabbit 1:100 Cell Signaling #9701 
α-fibrillarin 
(C13C3) - rabbit 1:400 Cell Signaling #2639 
α-cleaved 
caspase-3 
(D175) (5A1E) 
- rabbit 1:200 Cell Signaling #9664 
 
2.6.5.2 secondary antibodies 
 
antibody source dilution company Cat No. 
Goat-α-rabbit Alexa Fluor® 488 goat 1:500 Invitrogen A 11034 
Goat-α-mouse Alexa Fluor® 594 goat 1:500 Invitrogen A 11032 
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2.6.5.3 others 
 
name target dilution company Cat No. 
DAPI DNA 1:500 Sigma-Aldrich 32670 
Alexa Fluor® 546 phalloidin F-actin 1:80 Invitrogen A 22283 
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2.7 Rapamycin and CVT-313 treatment 
The mTOR pathway inhibitor rapamycin and the cdk-2 inhibitor CVT-313 [95], both 
dissolved in DMSO, were added to the medium of the cells 24 hours before harvesting 
them for further experiments. The final concentration of rapamycin was 100 nM [46] and 
2.5 µM of CVT-313 in the growth medium. To exclude an effect of the solvent, control 
cells were treated at the same time with an equal amount of DMSO. The concentrations of 
the rapamycin stock solutions was 100 µm and of CVT-313 it was 2.5 mM. They were 
stored at -20°C 
 
 
 
2.8 Statistic analysis 
For statistic analysis we used GraphPad Prism 4 and Microsoft Excel 2008. Boxplots 
were created with GraphPad Prism 4. The box indicates the middle 50% of the data, 
which is from the lower (Q1) to the upper quartile (Q3); the line indicates the median 
(Q2); the whiskers show the smallest and largest observations.  
Bar graphs were created with Microsoft Excel 2008. All graphs are presented with 
standard deviations.  
Comparisons between different groups were calculated using a t-test (two tailed, paired),  
statistical significance is given with p-values ≤ 0.05. 
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3 Results 
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3.1 Establishing culture conditions for IMR-90 in collagen gels  
IMR-90 lung fibroblasts have not been cultured in collagen gels in our lab. Therefore we 
had to establish appropriate culture conditions. We decided to use either single-cell 
suspension cultures in collagen gel or to use spheroid collagen gel invasion assays.  We 
kept the collagen gel I composition as well as the culture medium the same, whereas we 
varied cell number per spheroid, spheroid number per collagen gel and the duration of 
aggregation into spheroids to determine the most suitable conditions to follow outgrowth 
of the cells from the spheroids into the collagen I matrix.  
In a pilot experiment, we used spheroids containing 1000 cells each, which we let 
aggregate for 24 hours prior to seeding 300 spheroids into one collagen gel. In this 
experiment it took 8 days until only a minority of the cells were invading into the 
collagen gel (Figure 3.1 a). It is known in the literature that fibroblasts undergo a process 
called nemosis, when they are cultivated in spheroids for extended time periods (Figure 
3.2). Nemosis is described as a phenomenon, which display features of necrosis and 
apoptosis at the same time and has so far been observed only in vitro (for further 
informations on nemosis see chapter 1.2.1). Since we wanted to establish a system in 
which we can measure and quantify the outgrowth of cells into collagen gels, we strictly 
wanted to avoid dying cells. Therefore, we reduced the spheroid aggregation time to 14 
hours. In addition we varied the amount of spheroids embedded into one collagen gel 
from 100 to 200 or 300 (Figure 3.1 b-d). Using these conditions, cells started to migrate 
from the spheroids into the collagen gel even on the first day, indicating that the shorter 
aggregation time was beneficial for the survival of the cells in the spheroids. However, 
when 100 spheroids were seeded only a few cells invaded the collagen gel. In the 
collagen gels harbouring 200 or 300 spheroids, many cells were exiting the spheroid and 
invading into the collagen gel. It appeared that with increasing amounts of spheroids 
seeded the amount of cells invading increased. With 300 spheroids/gel there were so 
many invading cells after only two days, which resulted in an intermingling of migrating 
cells between neighbouring spheroids, which hindered accurate quantification. Despite 
the presence of invading cells the spheroid cores looked very condensed and appeared as 
very dark structures, which indicated still dying cells in the sphere. 
Based on these results we decided to let the cells undergo a shorter aggregation time and 
to use 200 spheroids per collagen gel. In a next experiment we used 1,500 cells per 
spheroid, 200 spheroids in one collagen gel and only 6 hours of aggregation (Figure 3.1 
e). With these parameters we got the best results, the cells looked vital and the spheroids 
61 
 
did not appear as condensed and dark structured as before, indicating that the number of 
dead cells decreased. We decided to use 1500 cells per spheroid, aggregated for 6 hours 
and 200 spheroids per gel as our standard condition for microscopic analysis and 
quantification of invasive structures. For flow cytometry (see chapter 3.2-3.3) we used 
300 spheroids per collagen gel and 3000 cells per spheroid to get a higher yield of cells.  
Single-cell suspension collagen gels were another 3D culture condition we used. 
Therefore, cells grown on tissue culture plates were trypsinised and 300,000 cells were 
embedded in collagen I gel (Figure 3.1 f). The lack of spheroid aggregation prevents cells 
from dying due to nemosis, even after a week of cultivation cells within these gels look 
vital. The only disadvantage is that a quantification of invasiveness is not possible. 
 
 
Figure 3.1: Establishing culture conditions for IMR-90 in collagen gels. a Pilot experiment with 
spheroids containing 1,000 cells each after 24 hours aggregation time. Thereafter 300 spheroids were 
embedded in collagen I gel. This picture shows the outgrowth after 8 days of cultivation. b Spheroids 
contained 3,000 cells after 14 hours of aggregation, 100 spheroids were embedded for this 
experiment and the picture was taken after one day. c. 200 spheroids with 3,000 cells each were 
embedded in collagen gel after 14 hours of aggregation and pictures were taken after day one. d 300 
spheroids with 3,000 cells each were embedded after 14 hours aggregation time; outgrowth was 
documented after one day. e Standard conditions for microscopic analyses are 200 spheroids each 
containing 1,500 cells after 6 hours of aggregation. This picture was taken after two days of 
cultivation. f For single-cell suspension collagen gels 300,000 cells were embedded in collagen gel, 
the picture was taken after two days. Scale bar represents 500 µm. 
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Figure 3.2: A Time course of human neonatal foreskin fibroblasts cultured as spheroids with 10,000 
cells for 72 hours in agarose-coated wells. Scale bar represents 100 µm. (figure taken from [25]) B 
Individual spheroids consist of 1,000 cells aggregated for 24 hours in non-adherent 96-well plates in 
methylcellulose-medium suspension. Thereafter 200 spheroids were embedded into collagen gel and 
images were taken for additional 7 days. Scale bar represents 250 µm. 
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3.2 Establishment of a harvesting protocol for flow cytometry analysis 
Our next intent was to set up a protocol for the analysis of the DNA content and the cell 
size distribution of IMR-90 for cell cycle analysis by flow cytometry. Therefore, the cells 
had to be isolated from the collagen gels and be available as single cell suspensions. We 
used collagenase B to enzymatically digest the collagen I network of the gels in order to 
release the spheroid structures and the invading cells.  
First of all we had to test, if the collagenase B treatment per se had any effects on our 
cells. Cells grown on tissue culture plates were trypsinised, washed with 1x PBS and 
divided into two aliquots. The cells in one sample were treated for 1 hour with 1.25 µg/µl 
collagenase B in PBS supplemented with Ca2+, Mg2+ and K, the other cells were 
resuspended in the incubation buffer without collagenase. Afterwards the cells were fixed 
in ethanol over night and stained with PI and analysed for DNA content and cell size 
distribution by flow cytometry. The collagenase treatment had no effect on the cell cycle 
distribution and the cell size as demonstrated by DNA content and forward/side scatter 
(size) analysis (Figure 3.3)  
After testing the collagenase B effect on cells, we set up a standard harvesting protocol. 
Collagen gels were washed twice with 1x PBS to remove residual growth medium and 
thereafter, incubated with 1.25 µg/µl collagenase B in PBS supplemented with Ca2+, Mg2+ 
and K. As soon as the collagen I network was enzymtically resolved after about two hours 
collagenase B activity was stopped with 0.5 M EDTA. The cells were transferred into a 
microcentrifuge tube and immediately put on ice. Cells derived from a single-cell 
collagen gel were centrifuged and fixed in ethanol over night, whereas, cells harvested 
from spheroid-assay gels were centrifuged and incubated in TE additionally to dissolve 
spheroid structures. Thereafter the cells were resuspended in growth medium to inhibit 
further enzymatic activity of TE, centrifuged and fixed over night in ethanol. All samples 
were stained with PI and analysed by flow cytometry. 
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Figure 3.3: Comparison of collagenase B treated and untreated cells. Trypsinised cells grown on tissue 
culture plates were washed with 1x PBS and divided into two aliquots. One sample was treated with 
1.25 µg/µl collagenase B dissolved in PBS supplemented with Ca2+, Mg2+ and K for one hour. The 
other sample was incubated for one hour with 1x PBS supplemented with Ca2+, Mg2+ and K for control 
purpose. Cells were fixed in ethanol, stained with PI and analysed by flow cytometry. A The overlay of 
both DNA contents shows the control sample in blue and the collagenase B treated cells in red. B 
Comparison of forward/side scatter contour plots of the control sample in blue and the treated sample in 
red.  
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3.3 IMR-90 in different culture conditions 
After we established a protocol for IMR-90 culture in collagen gels and a method to 
isolate cells from the gels as single cell suspensions for further analysis, we wanted to 
figure out whether IMR-90 grown in collagen gels, which represent the more in-vivo like 
situation, display a different phenotype compared to cells cultured on tissue plates. We 
were predominantly interested in differences in cell cycle distribution and cell size 
therefore FACS-analysis was our method of choice, because we could analyse both 
parameters in one step. 
IMR-90 cells from the same passage number were cultivated as spheroids (IMR90-sph), 
spheroids embedded into collagen gels (IMR90-sph-CG), single-cell suspension collagen 
gels (IMR90-cell-CG), sparse (IMR90-2D-sparse) and dense 2D cultures (IMR90-2D-
dense) on conventional plastic dishes. The spheroids were harvested after 6 hours of 
aggregation, one of two collagen gels with spheroids after one hour (IMR90-sph-CG-1h) 
and the second one like the single-cell collagen gel after two days of cultivation (IMR90-
sph-CG-2d). The sparse tissue culture plate was harvested the day after seeding, whereas 
the dense plate was harvested when cells reached 95% confluence.  
Before harvesting cell morphology was documented by microscopic pictures of the cells 
under all conditions. After fixation all samples were stained with PI and analysed by flow 
cytometry (Figure 3.4 A).  
The DNA-content profiles show that IMR90-2D-sparse shows a higher fraction of S 
(26.5%) and G2 phase (14.1%) cells than in all other conditions (Figure 3.4 B). As 
expected, IMR90-2D-dense display a cell cycle arrest in G1 (73.3%) with reduced S 
(20%) and G2 phase (3.26%). IMR90-single-CG display 8.6% S phase cells and 11.8% 
G2 phase cells. IMR90-sph and IMR90-sph-CG-1h show also a higher S phase (13.3%, 
13.8%) than IMR90-sph-CG-2d with 4.9%. IMR90-sph-CG-2d displays about 10% G2 
phase cells.  
Interestingly we found that forward scatter/side scatter profiles show that the granularity 
of the cells did not change significantly within IMR90-2D-sparse, IMR90-2D-dense, 
IMR90-cell-CG, IMR90-sph and IMR90-sph-CG-1h, whereas in IMR90-sph-CG-2d it is 
reduced (SSC) (Figure 3.4 C) concomitantly all cells cultured in collagen gels are smaller 
than cells grown on tissue culture plates (FSC) (Figure 3.4 D,E). IMR90-sph and IMR90-
sph-gel-1h display the same size, IMR90-single-gel is slightly smaller than the two 
mentioned before. IMR90-sph-gel-2d display a dramatic decrease in cell size as compared 
to cells grown on plastic; in addition they are also smaller than IMR90-single-gel. 
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3.4 Effect of rapamycin on spheroid invasion 
Next we asked whether the invasive potential of IMR-90 cells is dependent on the mTOR 
pathway. Therefore we incubated spheroids embedded in collagen gels with 100 nM of 
rapamycin [46]. Furthermore we used CVT-313, a specific cdk-2 inhibitor, which inhibits 
cell cycle progression in late G1, to determine whether cell proliferation is a prerequisite 
for the invasiveness of the fibroblasts. The inhibitors were added at three different time 
points. First, the inhibitors were added after the spheroids were embedded into the 
collagen gel. Second, rapamycin and CVT-313 were added during the course of spheroid 
aggregation (3 hours before harvesting spheroids) and third we pre-incubated the cells 
with the inhibitors on 2D one day before spheroid formation. 
 
3.4.1 Treatment after collagen gel polymerization  
When spheroids were embedded in collagen gel they were transferred into 24-well plates 
containing 1 ml of growth medium supplemented with 100 nM rapamycin, 2,5 µM CVT-
313 and DMSO as a control, respectively. After 3 hours, 24 hours and 42 hours the 
morphology was documented by microscopic pictures of the spheroids and invading cells. 
These pictures were afterwards analysed using CellD, a program that contains image 
acquisition tools and measurement functions (Figure 3.5 A). For determining the invasive 
area of individual spheroids measurements of the total area (including all cells exiting the 
spheroids) were performed followed by subtraction of the spheroid area. Statistical 
analyses were performed using Microsoft Excel 2008 and GraphPad Prism 4.  
The data presented in Figure 3.5 B show that after 3 hours in collagen gel spheroids 
invaded equally under all conditions tested. After 3 hours all conditions showed 
comparable invasion areas (DMSO = 2314.036 µm2, rapamycin = 1549.966 µm2, CVT-
313 = 1940.694 µm2). 24 hours after seeding CVT-313 displayed a significant reduction 
of invasive area compared to DMSO (p = 0.0017), whereas DMSO (18305.10 µm2) and 
rapamycin (18507.16 µm2) showed almost same invasion areas. After 2 days of 
cultivation rapamycin treated cells displayed significant reduction of the invasive areas 
compared to the control (p = 0.0012). At that time CVT-313 showed about 50% less 
invasion than DMSO, rapamycin displayed a 40% reduction of invasive area. 
 
68 
 
 
Figure 3.5: Time course experiment of spheroids treated after collagen gel polymerisation with 100 
nM rapamycin and 2.5 µM CVT-313, respectively. A Microscopic images with invasion areas marked 
in red. Scale bar represents 200 µm B Box plots showing spheroids of the individual conditions. The 
whiskars represents the highest and lowest outgrowht, the box the middle 50% of the data and the 
lines the mean values. Significant differences compared with DMSO are marked with stars. (n = 6) 
The barchart shows a summary of the mean values of invasive area over time. 
3.4.2 Treatment three hours before harvesting spheroids 
Since differences in invasion areas in rapamycin and CVT-313 treated cultures were 
clearly visible only after two days of incubation, we decided to pretreat the spheroids 
prior to embedding them into collagen gels with the inhibitors. This pretreatment 
eliminates potential diffusion problems, which might be present in the previous 
experiment. Therefore, rapamycin, CVT-313 or DMSO were supplemented to the growth 
medium three hours before harvesting the spheroids. When cells were embedded into 
collagen gel they were with 100 nM rapamycin, 2.5 µM CVT-313 and DMSO, 
respectively. Microscopic pictures were taken at different time points (Figure 3.6 A).  
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After 16 hours significant differences in invasive areas were detectable between DMSO 
and rapamycin (p = 0.0002) and CVT-313 (p < 0.0001), respectively (Figure 3.6 B). Both 
displayed decrease in invasive area compared to the control cells. Comparison of 
rapamycin and CVT-313 showed comparable invasion areas (rapamycin = 21396 µm2, 
CVT-313 = 18452 µm2). At day two there was no increase of invasion area in CVT-313 
treated cells, a 5% increase in rapamycin and 25% in DMSO compared to day one. After 
two days CVT-313 displayed 70% less invasion area, rapamycin 55% compared to 
DMSO. 
 
Figure 3.6: Time course of cells treated three hours before harvesting spheroids and after embedding 
them in collagen gels with 100 nM rapamycin and 2.5µm CVT-313, respectively. A Pictures of the 
different time points with the measured invasion area in red. Scale bar represents 500 µm. B Boxblots 
show invasive area of all measured spheroids, significant differences to DMSO are marked with stars. 
(n = 7) The barchart shows a summary of the mean values over time. 
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3.4.3 Over night treatment before spheroid aggregation 
To fully rule out that the incubation did not reach every cell in the previous experiments 
due to the fact that the cells were present as spheroids, we performed pretreatment of the 
cells before spheroid aggregation. The day before spheroid formation IMR-90 were 
incubated with 100 nM rapamycin or 2.5 µM CVT-313 or DMSO. Spheroid formation 
and subsequent cultivation in the gels were done in the presence of the inhibitors. 
Microscopic pictures were taken after 18 hours, 24 hours and 48 hours (Figure 3.7 A). 
Importantly the aggregation of the fibroblasts to spheroids was not influenced by the 
pretreatment with the inhibitors. 
After 18 hours rapamycin (p < 0.0001) and CVT-313 (p < 0.0001) showed half the 
invasion area than DMSO (Figure 3.7 B). While control cells with DMSO invaded 
constantly more until day 2, both, rapamycin and CVT-313, showed no significant 
increase in invasion area. In summary, we got 75% less area size in rapamycin and CVT-
313 treated cells, than in the control condition.  
In general, there were significant differences to the previous experiment, indicating that 
the over night pretreatment is necessary to efficiently target the cells with the inhibitors. 
The effects on invasion of the two inhibitors did not rule out that many of the cells died of 
apoptosis under the culture conditions and as a consequence displayed reduced invasive 
capacity. Experiments addressing apoptosis are presented below. 
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Figure 3.7: Time course of collagen gels treated with 100 nM rapamycin and 2.5 µM CVT-313, 
respectively. Cells were treated over night before spheroid formation and subsequently during 
aggregation and cultivation in collagen gels. A Microscopic images of spheroids with red marked 
invasion area. Scale bar represents 500 µm. B Boxplots showing evaluated data, significant differences 
compared with DMSO are signalised with stars. (n = 7) Barchart represents the mean values over time. 
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3.5 Collagen gels with siRNA treated cells 
Rapamycin is an inhibitor of mTORC1 activity and affects mTORC2 activity indirectly 
after long term incubation [45, 80, 87]. Therefore, we decided to perform more controlled 
experiments in which we interfered either with mTORC1 or mTORC2 activity. mTORC1 
activity can be inhibited by removing raptor from the mTORC1 complex and for 
mTORC2 by removing rictor [46]. We transfected the cells with raptor and rictor siRNA 
and used non-targeting control (NTC) siRNA for comparison. Prior to phenotypic 
analysis of the invasive behaviour in collagen gels the effectiveness of the individual 
knockdowns (k-d) was verified by Western blot analysis. 
Cells grown on plastic for 72h after transfection were trypsinised, lysed and subjected to 
Western blot analysis. We detected raptor, rictor, the downstream target phosphorylation 
sites T389 of p70 S6K for mTORC1 and S473 of AKT for mTORC2 (Figure 3.8 A). The 
total protein of AKT and p70 S6K served as controls for equal loading. For densitometric 
quantification the values of NTC condition was set to 100% for the individual antibodies 
in order to get comparable data. 
An efficient knockdown of raptor and rictor protein was detectable (Figure 3.8 B). In 
accordance to the raptor k-d, downstream signalling of mTORC1 was also affected. The 
phosphorylation status of p70 S6K in the raptor knockdown is specifically lower than in 
the other two lysates. Concomitantly, there is a shift in the electrophoretic mobility of the 
total p70 S6K, which is associated with the dephosphorylated form of p70 S6K. In 
addition, there is an increase of 80% of AKT S473 phosphorylation in the raptor 
knockdown cells, which is the expected consequence of the lost negative feedback loop of 
active mTORC1. In the rictor knockdown phosphorylation of the mTORC2 direct target 
AKT at S473 is massively decreased. Taken together, these data indicate that rictor and 
raptor knockdown was efficient and resulted in the expected changes in downstream 
signalling.  
 
73 
 
 
Figure 3.8: A Westernblot analysis of IMR-90 cells transfected with siRNA for raptor and rictor 
knockdown, NTC served as control. Samples were tested to determine the effectiveness of the individual 
knockdowns. B For densitometric quantification the measured values were normalised to p70 S6K in the 
raptor k-d and to AKT in the rictor k-d, respectively. Values of NTC were set to 100% for comparison 
purpose. The upper barchart shows the raptor k-d, its downstream target p70 S6K (T389) and AKT, the 
lower barchart represents rictor k-d, the downstream target p AKT (S473) and p70 S6K. 
 
In further experiments we tested the consequences of raptor and rictor k-d in the collagen 
gel invasion assay. Therefore 72 hours after transfection, the cells were splitted and used 
for spheroid formation 24 hours later and were subsequently embedded into collagen gels. 
Besides raptor, rictor and NTC siRNA cells were treated only with the transfection 
reagent Lipofectamine RNAiMAX, determining whether the treatment itself has an effect 
on the invasiveness of the cells. Pictures were taken after 16 hours, 24 hours and 48 hours 
(Figure 3.9 A). 
After 16 hours of cultivation DMSO (41879.96 µm2) and RNAiMAX (43075.53 µm2) 
invaded comparably (Figure 3.9 B). Raptor and rictor k-d showed a significant decrease 
in invasion area (raptor p = 0.001; rictor p < 0,0001). During the next days they invaded 
the surrounding matrix slower than the two control samples. After two days raptor k-d 
cells showed an invasion area 30% less than the control and the rictor k-d a reduction of 
60% compared to NTC. RNAiMax displayed no significant decrease compared with NTC 
during cultivation, indicating that the treatment has no effect on the behaviour of the cells. 
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Figure 3.9: Time course experiment with raptor, rictor and NTC siRNA treated cells. Cells were 
transfected for 72 hours, for control purpose cells were incubated with the transfection reagent 
Lipofectamine RNAiMAX, instead of siRNA. After transfection cells were trypsinised, aggregated and 
embedded into collagen gel. A Microscopic images of spheroids with red marked outgrowth. Scale bar 
represents 500 µm. B Statistical evaluation presented by boxplots. Significant differences compared to 
NTC are marked with stars. (n = 7) The data used for the barchart is shown as mean values. 
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3.6 Comparison of the invasion rates 
After collecting data from all time course experiments described above (rapamycin and 
CVT-313, siRNA experiments) we were able to compare the rate of invasion of IMR-90 
cells into the collagen gels. 
In order to get results, which are directly comparable, the maximum invasion area after 2 
days of culture under DMSO and NTC control conditions was set to 100%. Then we 
composed graphs, which show a time course of the increase of invasion area.  
The data presented in Figure 3.10 shows that the effect on invasion area occurred earlier 
when cells were pretreated over night with rapamycin and CVT-313, treatment after 
collagen gel polymerisation displayed the lowest effect. Cells, which were treated in the 
middle of spheroids aggregation with CVT-313, stopped invading the collagen gel after 
16 hours of incubation completly; rapamycin treated cells invaded slower but steadily. 
With siRNA treated cells invaded without stagnation, but never reached the invasion area 
of NTC or RNAiMAX control. 
 
 
Figure 3.10: Comparison of the invasion rates under different conditions. The x-axis presents the 
elapsed time in hours, the y-axis the percentage compared to DMSO and NTC after 2 days. Values 
were taken from the individual experiments from chapter 3.4 and 3.5. 
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3.7 Detection of apoptosis upon mTOR inhibition 
As mentioned above, induction of apoptosis in fibroblasts grown in 3D could be the 
reason for decreased invasion upon mTOR inactivation with rapamycin. Previous 
experiments have shown that IMR-90 cells cultivated on plastic dishes did not show an 
increase of apoptosis upon rapamycin treatment [96]. Apoptosis in IMR-90 cells grown in 
3D was so far not addressed. Therefore we determined how many cells underwent 
apoptosis upon rapamycin and CVT-313 treatment in the 3D cell culture setting. After 
collagen gel fixation cells were stained with α-cleaved caspase-3 and nuclei were 
visualized with DAPI. After capturing images with a confocal microscope two different 
types of DAPI stained nuclei were found within the spheroids, normal shaped nuclei and 
condensed nuclei. Those condensed nuclei were visible as small dots in between normal 
shaped nuclei (see Figure 3.11 B).  
Next we counted normal nuclei, condensed nuclei and cleaved caspase-3 positive cells, 
which we separated into the two categories “cleaved caspase-3 positive - normal nuclei” 
and “cleaved caspase-3 positive - condensed nuclei” (Figure 3.11 B).  
The total number of cleaved caspase-3 positive cells (Figure 3.11 C) increased from 2.1% 
in DMSO to 8.7% upon rapamycin treatment. CVT-313 treated cells revealed 14.5% 
cleaved caspase-3 positive cells. The analysis of cleaved caspase-3 positive cells, which 
display condensed nuclei revealed a comparable increase (Figure 3.11 D). In DMSO 77% 
of the positive cells concomitantly display condensed nuclei, in rapamycin 88.6% and in 
CVT-313 97.8% showed condensed nuclei. In relation to all counted nuclei, that are all 
normal nuclei and condensed nuclei, the number of condensed nuclei increased from 13% 
in DMSO to 44% in rapamycin to 75% in CVT-313 treated spheroids whereas the number 
of cleaved caspase-3 positive cells is specifically lower (2.1% in DMSO, 8.7% in 
rapamycin and 14.5% in CVT-313 treated cells) (Figure 3.11 E).  
As caspase-3 activation occurs early during apoptosis we defined cleaved caspase-3 
positive cells with normal nuclei as early apoptotic cells and cleaved caspase-3 positive 
cells with condensed nuclei as late apoptotic cells. Cells with condensed nuclei and 
without positive cleaved capase-3 signal died due to caspase-3-independent pathways. 
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Figure 3.11: Spheroids treated with 100 nM rapamycin, 2.5 µM CVT-313 and DMSO were fixed after 2 
days with 4% PFA. They were stained with cleaved caspase-3 and DAPI and microscopic images were 
taken with a confocal microscope. Thereafter cleaved caspase-3 positive cells and DAPI stained nuclei 
were counted. (DMSO n=592, rapamycin n=515, CVT-313 n=645) A Confocal microscopic images of 
cleaved caspase-3 and DAPI stained spheroids, which were treated with 100 nM rapamycin and 2.5 µM 
CVT-313 after embedding into collagen gel. Scale bar represents 200 µm. B Two groups of cleaved 
caspase-3 positive cells were found, one group consists of normal nuclei the other one of condensed 
nuclei. C Barchart of the number of cleaved caspase-3 positive cells compared to all counted nuclei in 
the individual conditions. D Barchart showing the number of cleaved caspase-3 positive cells with 
condensed nuclei (dark gray) in relation to all positive cells (white) in the individual conditions. E 
Barchart showing a comparison off cleaved caspase-3 positive cells (dark gray), condensed nuclei (light 
gray) and all counted nuclei (normal nuclei and condensed nuclei) representing 100% (white).  
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3.8 Immunofluorescence stainings 
Next we asked whether mTOR components are expressed and where they are located in 
cells grown in 3D culture compared to cells cultured on plastic. Therefore we cultivated 
cells on tissue culture slides (2D) and as single-cell suspension collagen gels (3D) both 
treated with and without 100 nM rapamycin for 48 hours. After fixation cells were stained 
with various antibodies for mTOR pathway components, nuclei were counterstained with 
DAPI and the actin cytoscelleton was visualised by staining of F-actin with fluorescently 
labelled phalloidin.  
 
3.8.1 Secondary antibody control 
To evaluate the amount of background staining caused by the secondary antibody, cells 
were stained with secondary antibody alone, nuclei were counterstained with DAPI and 
the cell body was visualised with phalloidin in 2D (Figure 3.12). The cells were examined 
using a confocal microscope. As expected secondary antibody alone showed almost no 
background staining in 2D as well as in 3D. 
 
Figure 3.12: Secondary antibody control for background staining in cells cultured on plastic slides and in 
single-cell suspension collagen gels. Alexa Fluor 546 phalloidin was not tested in 3D. Scale bar 
represents 50 µm. 
 
3.8.2 mTOR 
In cells grown on tissue culture plates mTOR is located in a vesicle-like manner with a 
predominantly expression in the perinuclear region and a smaller fraction in the 
periphery, within the nucleus there is no accumulation visible (Figure 3.13). In rapamycin 
treated cells the staining pattern is similar, despite a more pronounced vesicular 
appearance. This is in close accordance to data from literature. mTOR predominantly 
localises to the endoplasmic reticulum and the golgi apparatus and only a small fraction 
of mTOR is present in the nucleus [97]. The distribution of mTOR in IMR-90 cells grown 
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in collagen gels show an identical staining pattern. Increased vesicular appearance of 
mTOR was also present in cells treated with rapamycin.  
 
Fig. 3.13: mTOR distribution in cells cultured on tissue plates and in single-cell suspension collagen 
gels, both treated with and without 100 nM rapamycin. Alexa Fluor 546 phalloidin was not tested in 3D 
treated with rapamycin. Scale bar represents 50 µm. 
 
3.8.3 pAKT S473 
In 2D AKT phosphorylated at S473 is located in the cytoplasma with predominantly 
accumulation in the cell protrusions in the periphery of the cells (Figure 3.14). This is in 
accordance to data from the literature [98]. The signal is increased after treatment with 
rapamycin as expected. This is caused by the loss of the negative feedback-loop of p70 
S6K towardss IRS1 upon mTOR inhibition (see chapter 1.3.6). In 3D the situation is 
similar, phospho-Akt-S473 is located in the cytolasma with increased staining intensities 
in cell protrusions. The increase of AKT S473 phosphorylation upon rapamycin treatment 
is also recapitulated in fibroblasts grown in collagen gels. 
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Figure 3.14: pAKT S473 distribution in cells cultured on tissue plates and in single-cell suspension 
collagen gels treated with and without 100 nM rapamycin. Scale bar represents 50 µm.  
 
3.8.4 AKT 
In 2D AKT is distributed throughout the whole cell with accumulation either within the 
nucleus or bound on its membrane (Figure 3.15). This is in accordance to data from 
literature [99]. Treatment with rapamycin does not change its localisation. Whereas AKT 
localised in the nucleus seems to be increased in 3D culture.  
Akt was not tested in collagen gels treated with rapamycin. 
 
Figure 3.15: Localisation of the total protein of AKT in cells cultured on tissue plates and in single-cell 
suspension collagen gels with and without 100 nM rapamycin treatment. Scale bar represents 50 µm. 
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3.8.5 pS6 S240/244 
In fibroblasts grown on a 2D surface S6 phosphorylated at S240/244 is localised in the 
cytolasma (Figure 3.16). The nuclei show a weak signal, which is not a proof for pS6 
localisation within the nuclei maybe it is resides behind it. After rapamycin treatment the 
phosphorylation of S6 at S240/244 is undetectable. This is in accordance with 
biochemical data from IMR-90 cells grown on plastic dishes [46]. The same situation can 
be observed in 3D culture. Untreated cells show a bright signal with the same distribution 
compared to 2D and a lack of signal after rapamycin treatment. Biochemical studies in 
IMR90 cells [100] and immunofluorescence stainings in human Hep2 cells [101] 
demonstrated that S6 and S6 S240/244 are predominantly localised within the nuclei and 
the nucleoli. To be sure that the lack of signal in the nucleoli in our IF analysis was not 
caused by insufficient antibody penetration of the cells we used a fibrillarin antibody. 
Fibrillarin is a component of a nucleolar ribonucleoprotein particle [102]. Cells from the 
same experiment were stained with identical protocols with either α-fibrillarin antibody or 
α-pS6 S240/244 (Fig 3.17). The fibrillarin antibody stained the nucleoli of the cells, 
whereas no pS6 S240/244 staining within the nuclei was observable, indicating that the 
staining protocol per se was not responsible for the lack of staining and antibodies could 
diffuse into nucleolar structures.  
 
Figure 3.16: Localisation of ribosomal S6 phosphorylised at S240/244 in cells cultured on tissue plates 
and in single-cell suspension collagen gels with and without 100 nM rapamycin treatment. Alexa Fluor 
546 phalloidin was not tested in 3D collagen gels treated with rapamycin. Scale bar represents 50 µm. 
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Figure 3.17: Fibrillarin and pS6 S240/244 stained cells grown on plastic slides in order to test the 
protocol for the ability of nuclear staining. Scale bar represents 50 µm. 
 
3.8.6 4E-BP1 
In 2D 4-EBP1 is localised throughout the cytoplasm and the nucleus (Figure 3.18). The 
same distribution is visible in rapamycin treated cells. In 3D the situation is equal to 2D, 
protein localisation in the cytoplasm and the nucleus. This localisation pattern is also 
proposed in the literature; furthermore they showed with immunofluorescence analyses 
that 30% of the total number of protein resides within the nuclei [103].  
4E-BP1 was not tested in rapamycin treated collagen gels. 
 
Figure 3.18: Localisation of 4E-BP1 in cells cultured on tissue plates with and without treatment with 
100 nM rapamycin and in single-cell suspension collagen gels. Scale bar represents 50 µm. 
 
3.8.7 p-H3 S10 
Histone H3, H2A, H2B and H4 are part of the core particles of nucleosomes where DNA 
is wrapped around. Nucleosomes are linked together with H1 for further folding into 
chromatin fibers. During mitosis all H3 molecules become phosphorylated in the n-tail 
site at S10 [104, 105]. Therefore, phospho-H3 (p-H3) can be used as a marker for 
dividing cells. Figure 3.19 shows that in the three tested conditions phosphorylated H3 
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molecules can be found indicative for cell proliferation. The aim of this staining was to 
calculate a mitotic index showing how many cells undergo mitosis in the individual 
conditions, but the number of stained H3 was too small for statistical analyses. 
p-H3 was not tested in rapamycin treated collagen gels. 
 
Figure 3.19: Localisation of phosphorylated histone H3 at S10 in cells cultured on tissue plates and in 
single-cell suspension collagen gels with and without 100 nM rapamycin treatment. Scale bar represents 
50 µm. 
 
3.8.8 Cleaved caspase-3 
Caspases are responsible for apoptosis. They can be classified as initiator or executor 
molecules. To activate the executor caspase-3, leading to apoptosis, cleavage mediated by 
initiator caspases is needed [106]. Figure 3.20 shows staining of the activated form 
cleaved caspase-3. The number of apoptotic cells was too small to calculate an apoptotic 
index. Cleaved caspase-3 was not tested in 2D. 
 
Figure 3.20: Localisation of cleaved caspase-3 in cells cultured on tissue plates with and without 
treatment with 100 nM rapamycin and in single-cell suspension collagen gels. Scale bar represents 50 
µm. 
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4. Discussion 
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Threedimensional (3D) cell culture is a useful tool to study physiological aspects of many 
cellular features under in-vitro conditions; for example to investigate the biomechanical 
functions or cell-matrix interactions. It is supposed to resemble a tissue like environment 
mimicking extracellular matrix (ECM) features, which are found in-vivo, since 
environment and shape of a cell can determine its behaviour and gene expression [14]. 
We are interested in molecular changes of mTOR signalling during 3D culture of IMR-90 
lung fibroblasts and the effects of mTOR pathway inhibition in this experimental setting. 
Therefore we produced collagen gels with collagen I as a main component since our cells 
are derived from a fetal lung and the lung interstitium contains collagen type I [3]. Our 
intent was to analyse the differences between 2D and 3D culture due to the fact that IMR-
90 were isolated, they resided in a 3D environment and were put in flat tissue culture 
plates afterwards. Furthermore we were interested in the invasion of these cells, when 
they were embedded into collagen gels. 
 
4.1 Setup of a 3D model system 
We wanted to use a novel approach to study the behaviour and invasive properties of 
fibroblasts in collagen gels. Therefore we decided to form spheroids from fibroblasts and 
to embed these spherical structures into collagen gels. The invasive capacity could then 
be determined by measuring the area of cells, which left the spheroids and migrated in an 
astral manner away from the spheroid surface through the extracellular matrix. Our first 
intent was to establish appropriate culture conditions for IMR-90 in collagen gels, since 
they have not been cultured in 3D in our lab before. We cultivated them as single-cell 
suspension collagen gels and for invasion assays as spheroids embedded into collagen 
gels. One problem we had to deal with was the induction of a process called nemosis in 
the fibroblasts when cultivated in aggregates. Vaheri, et al. described that culturing 
fibroblasts in aggregates activates a programmed necrosis-like pathway called nemosis 
(chapter 1.2.1) leading to decomposition of the spheroids and the cells within them [25]. 
We observed very similar features, when IMR-90 cells were incubated as aggregates in 
96-well plates. In several optimisation steps we reduced the aggregation time to 6 hours. 
Using these conditions the spheroids were still formed but the cells did not display 
apoptotic structures. Many cells invaded the surrounding gel and quantification was 
possible. Our standard conditions for spheroid invasion assays were as following: 1,500 
cells, 6 hours of aggregation and 200 spheroids per collagen gel. Phenotypically there 
were no signs of cell death detectable, however, it is not clear whether some cells died 
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due to nemosis or apoptosis triggered by the aggregation process, therefore TUNEL 
analysis would be necessary to determine the exact number of dying cells in the spheres.  
As mentioned above IMR-90 were also cultured as single-cell suspension collagen gels. 
Therefore 300.000 cells in single-cell suspension were embedded into collagen gel. Due 
to the lack of spheroid formation cells within this culture condition do not undergo 
nemosis and even after a week of cultivation they look vital. Therefore, these cultivation 
parameters could be used for further experiments for single-cell suspension collagen gels. 
 
4.2 Cell cycle distribution and cell size of IMR-90 cells in 3D 
Now that we were able to culture IMR-90 in collagen gels, we were interested whether 
cell cycle distribution and/or cell size was altered by 3D cultivation as compared to 2D 
culture. We used flow cytometry (FACS) to analyse cell cycle parameters and cell size 
distributions. For FACS analyses cells have to be available as single-cell suspension, 
therefore we established a protocol to isolate cells cultured in collagen gels. We could 
demonstrate that cell size parameters and cell cycle distribution were not affected by the 
isolation process. After establishing appropriate harvesting conditions for IMR-90 
fibroblasts, we were able to address whether 3D culture induced phentoypical as well as 
functional differences in the cells as compared to 2D culture. As described in chapter 3.3 
cell cycle analyses showed an increase of cells in G1 and a decrease in S and G2 phase 
cells in all collagen gels compared to cells from plastic cell culture dishes (figure 3.4). 
This is in close accordance to the literature; human skin fibroblasts cultured in collagen 
gels behaved very similar [48]. Higher fractions of G1 phase cells after 7 days of 3D 
cultivation were detected, indicating less proliferation [48]. Another study showed that 
polymerised collagen I suppresses fibroblast proliferation via an integrin - protein 
phosphatase 2A (PP2A) - TSC2 complex activating TSC2 by repressing its 
phosphorylation level leading to enhanced GAP activity towards Rheb and consequently 
to inhibited mTORC1 signalling towards S6K1 [107]. Primary human lung fibroblasts 
(HLF 210) were cultured on top of polymerised collagen matrices showing reduced levels 
of S6K1 posphorylation at T389, increased PP2A activity and reduced numbers of cells 
entering S-phase compared to fibroblasts cultured on monomeric collagen. Knock-down 
experiments and inhibition of PP2A revealed that reduced S6K1 phosphorylation is 
mediated through activated TSC2 [107]. In order to proof if these observations are an 
explanation for the reduction of proliferation within our experiments Western blot 
analyses with PP2A and TSC2 antibodies and further spheroid invasion assays with either 
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TSC2 knock-out cells or with TSC2 siRNA transfected IMR-90 are needed. However, so 
far the size of fibroblasts cultivated in collagen gels was never determined. FSC analysis 
demonstrated that all cells cultured in 3D display smaller cell size compared to 2D. 
Furthermore cells isolated from spheroids/astral outgrowths after two days of cultivation 
in collagen gels show the smallest cell size compared to all other conditions. This massive 
size reduction occurs only after long-term cultivation in collagen gels, one hour after 
embedding into collagen gels cells display the same cell size as after spheroid formation. 
Due to this observations cell shrinking caused by osmotic changes or isolation artefacts 
can be ruled out. The decrease in cell size might indicate changes in the mTOR-signalling 
pathway, as this pathway is involved in many cellular functions like regulating mRNA 
translation, ribosomal biosynthesis, proliferation and cell size via its downstream targets 
(see chapter 1.3; reviewed in [44]). As rapamycin is a highly specific inhibitor of mTOR 
function and has been shown to decrease the cell size and alter cell cycle progression in 
2D cultures in IMR-90 fibroblasts [46] this inhibitor is also well suited to study cell size 
regulation in 3D. Therefore further experiments are needed concerning cell cycle 
distribution and cell size analyses of rapamycin treated cells cultured in the same 
conditions as mentioned above and Western blot analyses of mTOR pathway components 
to identify different phosphorylation states and expression patterns in 2D and 3D. 
 
Due to the above mentioned decreased percentage of cells in S phase under 3D culture 
conditions we tried to quantify proliferation of cells cultured on tissue culture plates and 
in collagen gels. First we used phosphorylated histone H3 (p-H3) as a marker for cells 
undergoing mitosis [105]. Positive p-H3 (S10) cells were found in both culture conditions 
(Figure 3.19), but the number was too small for statistical analysis, since H3 is only 
phosphorylated during mitosis, which lasts only for 1-2 hours. For better quantification 
further experiments are needed using Bromodeoxyuridine (BrdU) incorporation in the 
individual conditions (tissue culture plates and single-cell suspension collagen gels) 
analysed by flow cytometry. Another possibility could be to detect incorporated BrdU 
with immunofluorescence analyses. The advantage of BrdU compared to p-H3 is that 
cells start to incorporate BrdU during S-phase and that after a complete cell cycle they do 
not lose the incorporated signal. This leads to a higher number of positive cells and the 
possibility to calculate the proliferation rates in the individual conditions. Furthermore 
Western blot analysis could be performed detecting proliferation markers like pRB, cyclin 
A, cyclin D1 and cdk inhibitors like p21 and p27. 
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4.3 Does mTOR signalling alter invasion? 
IMR-90 cultivated in collagen gels display spindle like bipolar morphology and invade 
the collagen gel. For quantification of the invasion areas we used a spheroid assay, 
aggregated cells were embedded into collagen gel and cells start to exit the spheroids and 
invade the gel. With this assay invasion can be measured in microscopic images 
determining the area of invasive structures using standard microscopy software. 
Our intent was to observe whether the amount of invasion of IMR-90 into the surrounding 
collagen gel depends on the mTOR pathway or simply on proliferation of the cells, 
leaving the spheroid. Therefore we used a small molecule cell cycle inhibitor (CVT-313) 
as control. In collagen gels, which were treated after polymerisation, the effect of the 
treatment with the cdk-2 inhibitor CVT-313 occurred after one day (Figure 3.5), effects of 
rapamycin were visible two days after treatment. The reason for the late onset of the 
rapamycin and CVT-313 effects, respectively, might be explained with a diffusion effect. 
It could take longer until the inhibitors diffuse through the collagen gels and reach the 
cells compared to the situation in tissue culture plates. 
To eliminate these potential diffusion problems, cells were pretreated during spheroid 
formation (Figure 3.6) and effects occurred earlier compared to the treatment after 
collagen gel polymerisation. The mTOR and cdk2 inhibition showed less invasion 16 
hours after embedding the pretreated spheroids in the collagen gels. This effect could be 
explained with an already inhibited mTORC1 complex, when cells were embedded, 
however mTORC2 activity is not affected at that time. Rosner et al. showed that even one 
hour after rapamycin treatment the first effects on mTORC1 dependent downstream 
signalling (phosphorlyation of p70 S6K at T389) were visible [46]. 
To rule out, that the inhibitors did not reach every cell within the spheroids to the same 
extend, cells were pretreated in tissue culture plates the day before aggregation. This 
experiment showed that spheroid formation does not depend on the mTOR pathway; the 
spheroids displayed the same morphology compared to untreated spheroids. This 
experiment revealed the strongest inhibitory effect in rapamycin treated cells. CVT-313 
treated cells showed no difference compared to the previous mentioned experiment. Due 
to the prolonged treatment within this experiment mTORC1 activity is decreased and the 
assembly of mTORC2 complexes is diminished, when spheroids were embedded into 
collagen gels [45]. It seems that the effect of rapamycin is more prominent, when both 
complexes are affected. Since rapamycin is an inhibitor of mTORC1 activity and affects 
mTORC2 after prolonged treatment, we decided to perform more controlled experiments 
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by interfering the assembly of the individual complexes via knock-down (k-d) 
experiments.  
We used specific siRNA’s against raptor and rictor to determine the effect of 
independently inhibited mTORC1 and mTORC2 activities. Removing raptor from the 
complex inhibited mTORC1 activity and removing rictor inhibited mTORC2 [46]. 
Western blot analyses of lysates from siRNA treated cells showed significant knock-
downs of raptor and rictor (Figure 3.8). Furthermore the main downstream target of 
mTORC1; p70 S6K (T389) and one target of mTORC2; pAKT (S473) displayed 
decreased activity in the respective knock-downs. In the raptor knock-down fibroblasts, 
there was a mobility shift of p70 S6K visible, which is associated with the electrophoretic 
mobility of its dephosphorylated form and concomitantly there was an induction of 
phosphorylated AKT, caused by the loss of the negative feedback loop via IRS (see 
chapter 1.3.6). These data indicated that raptor and rictor knock-downs were efficient and 
resulted in the expected changes in downstream signalling. 
Our next intent was to test the migratory potential of siRNA treated cells, which we used 
in the spheroid-based invasion assay (Figure 3.9). We looked at effects at 16 hours after 
embedding the spheroids into the collagen gels. The invasion areas of rictor k-d spheroids 
were smaller as compared to that of raptor k-d spheroids. This indicates a dependence of 
invasion rather on mTORC2 than on mTORC1. However, the minor invasion rate of 
rictor siRNA transfected cells could also be explained with a higher apoptosis rate within 
those cells. mTORC2 and PDK1 activate AKT through phosphorylation of S473 and 
T308 leading to phosphorylation of its downstream target BAD, thereby inhibiting its 
pro-apoptotic function (see chapter 1.3.4). Reduced AKT activity caused by the rictor k-d 
could result in decreased BAD phosphorylation and increased pro-apoptotic function. To 
verify this thesis further experiments like Western blot analyses are needed. 
In general the reduction of invasion within the knock-down experiments is not as high as 
in rapamycin treated cells. This fact can be explained with two different effects of 
rapamycin on the mTOR pathway, it inhibits mTORC1 kinase activity and activates 
PP2A leading to active dephosphorylation of p70 S6K and 4E-BP1 [83]. This accelerates 
the effect, so that the decrease of p70 S6K activity is visible as soon as 30 min. after 
treatment [46]. Whereas in knock-down experiments there is always a fraction of intact 
protein left. 
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4.3.1. Cell death and apoptosis 
In spite of the shortened aggregation time the spheroids embedded in collagen gels looked 
condensed and dark structured after two days of cultivation by rapamycin and CVT-313 
treatment. It was not clear how many cells died due to the culture conditions and the 
additional rapamycin and CVT-313 treatment, respectively. Previous experiments have 
shown that IMR-90 cultured on tissue culture plates do not show increased apoptosis after 
rapamycin treatment [96], however these experiments were not addressed in cells cultured 
in 3D so far. Therefore we determined how many cells underwent apoptosis in collagen 
gels treated with rapamycin and CVT-313 (Figure 3.11). DNA staining of spheroids 
revealed two morphological different types of nuclei, normal shaped nuclei and 
condensed nuclei (Figure 3.11 B). Chromatin condensation occurs in cells, which undergo 
apoptosis due to stepwise DNA fragmentation. For differentiation between early and late 
apoptotic cells additional propidium iodide (PI) staining is necessary since late apoptotic 
cells lose their membrane integrity so that PI can intrude the cells and chromatin stains 
pink-white, caused by the merging of the colours red (PI) and blue (DAPI) [108]. 
Execution of DNA degradation can be achieved caspase-dependent or caspase-
independent [108]. We found a higher apoptosis rate in CVT-313 treated cells compared 
to rapamycin treated and control spheroids. Furthermore in all three conditions there were 
more condensed nuclei than cells, which were positive for cleaved caspase-3 and not all 
caspase-3 positive cells displayed condensed nuclei. Since caspase-3 activation occurs 
early during apoptosis [109] and DNA condensation is a later event, our data could show 
early and late apoptotic cells. Early apoptotic cells could be defined as cleaved caspase-3 
positive showing normal nuclei and late apoptotic cells as cleaved caspase-3 positive 
displaying condensed chromatin. Consequently, negative cleaved caspase-3 staining and 
condensed nuclei might indicate a caspase-3-independent pathway, like nemosis [25]. For 
further differentiation of late apoptotic cells additional PI staining is necessary to observe 
intact membrane integrity or its loss. 
Additional experiments addressing the role of apoptosis in invasion could be a treatment 
of cells with Z-VAD-FMK, a broad range caspase inhibitor, which binds irreversible to 
the catalytic site of caspases [110]. Thereafter these cells could be analysed in the 
spheroid-based invasion assay. This experiment would show if the decrease in invasion 
area after CVT-313 and rapamycin treatment occurs due to the high apoptosis rate or due 
to the inhibition of cdk2 and mTOR. Furthermore cleaved caspase-3 expression could be 
determined by Western blot analysis. 
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4.3.2 Expression and localisation of mTOR pathway components in IMR-90 in 3D 
Since there is a massive decrease in cell size within cultivation in collagen gels Western 
blot analyses of mTOR pathway components are needed for further understanding of the 
differences in the individual culture conditions. As first hints cells cultivated in 2D and in 
3D were stained with antibodies against pathway components (see chapter 2.6.2) to detect 
the amount and localisation of mTOR pathway components 
mTOR was located within the cytoplasma in vesicle-like structures near the nucleus in all 
tested conditions. No signal was detectable within the nuclei. After rapamycin treatment 
an increase of the vesicle-like structures is visible. This is in close accordance to the 
literature, where it is known that only a small fraction of mTOR is localised within the 
nucleus and that it is predominantly bound to the endoplasmic reticulum and the golgi 
apparatus in the cytoplasma [97].  
Phosphorylated AKT at S473 was localised preferentially in the lamellipodial protrusions, 
but without nucleus’ signals in 2D and in 3D. After rapamycin treatment the signal 
increased especially in the protrusions, which is the expected consequence of the lost 
negative feedback loop (reviewed in [44, 49]). The only difference is that the distribution 
within cells cultured in collagen gels was not as even as in 2D, it looked like vesicle-like 
structures. It is described in the literature that phosphorylated AKT at S473 is localised 
predominantly in the protrusions of the human breast cancer cell line MCF-7, which is in 
accordance to our data [98]. 
Total AKT is distributed throughout the whole cells, with accumulation in or around the 
nuclei in all tested conditions and without changes after rapamycin treatment (Figure 
3.15). In 3D the signal within the nuclei seems to be accumulation increased. Our data is 
in accordance to the literature [99]. 
In 2D and in 3D the phosphorylation of S6 at S240/244 is located throughout the 
cytoplasma (Figure 3.16). As expected after rapamycin treatment there is no signal left. 
This is in accordance with biochemical data from IMR-90 cells grown on plastic dishes 
[46]. Immunofluorescence staining in human Hep2 cells [101] and biochemical studies in 
IMR-90 cells [100] showed a S6 and pS6 S240/244 localisation within the nuclei [100, 
101]. In our samples there were no stained pS6 proteins within the nuclei visible, whereas 
a α-fibrillarin antibody stained the nucleoli as described in the literature [102]. New data 
in our laboratory indicate that the lack of staining is a fixation artefact, since pS6 signal 
within nucleoli in aceton/methanol (1:2) fixed IMR-90 is clearly visible (unpublished 
data).  
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4E-BP1 is localised in 2D and 3D in the whole cells showing accumulations within the 
nuclei, which is in close accordance to the literature [103]. Furthermore it was calculated 
that 30% of the total 4E-BP1 protein amount is localised within the nuclei [103]. 
Rapamycin treatment did not change its distribution. 
In summary there were two differences between cells cultured on tissue plates and cells 
from single-cell suspension collagen gels. The first one concerns the total protein AKT. 
In 3D it seems as if more protein is resided within the nuclei. The second one is that 
pAKT displayed more vesicle-like structures in 3D compared to 2D. All these data do not 
show severe differences in mTOR signalling components and cannot explain the size 
reduction when IMR-90 are cultivated in collagen gels, however these are only 
microscopic observations and quantitative changes are had to evaluate in this setting. For 
evaluation of the localisation within the nuclei in 3D of the total protein AKT a 
fractionation of cytoplasm and nuclei would be necessary with following Western blot 
analyses. 
In summary, the cell size of IMR-90 fibroblasts is drastically reduced when cells are 
cultured on 2D compared to 3D culture. After two days of cultivation in collagen gels the 
cell size is dramatically decreased and we can see changes in the granularity of the cells. 
Furthermore cells slow down proliferation. These data indicate changes in the mTOR 
pathway, since it is involved in regulation of cell size and cell cycle (reviewed in [44]). 
Immunofluorescence analyses of pathway components in 2D and in 3D do not show any 
massive differences in the distribution of the proteins, but for quantification of the protein 
amount we need to perform Western blot analyses. So far we only have preliminary data 
on Western blots, because protein lysates of cells out of collagen gels are technically 
demanding and so far the amount of protein was too less to warrant proper analyses. 
When IMR-90 are cultured as spheroids in collagen gels they start to invade the 
surrounding gel. After treatment with rapamycin they display less invasion. The amount 
of reduction depends on the time when the treatment starts. The biggest effect is visible 
when cells were treated the day before aggregation, due to inhibition of mTORC1 [51] 
and diminished mTORC2 activity [55, 56]. Accordingly, knock-down experiments show 
that the effect is more severe when mTORC2 is down regulated compared to knock-
downs of mTORC1. Until now the reasons for this results are unexplained and further 
investigation is needed. The cdk-2 inhibitor CVT-313 achieves a decrease of invasive 
area. Immunofluorescence analysis of collagen gels treated with DMSO, rapamycin and 
CVT-313 shows that CVT-313 treated spheroids display the highest number of cleaved 
94 
 
caspase-3 positive cells. Concomitantly the number of condensed nuclei with negative 
caspase-3 staining increased, indicating that they died due to caspase-3-independent 
pathways. The explanation for the low invasion rate of CVT-313 treated cells could be 
the high amount of dead cells within the spheroids, since there are only few cells left to 
invade the collagen gel. 
To fully address which cellular function is altered upon mTOR inhibition in fibroblasts 
grown in collagen gels, we need further cell cycle analysis (FACS, BrdU incorporation), 
migration analysis and apoptosis analysis.  
 
4.4 Perspectives 
Since there are many unexplained observations our next intent will be to establish a 
harvesting method for NP40 lysis of collagen gels. Thereafter lysates of cells cultured in 
tissue culture plates and in collagen gels will be used for Western blot analyses of mTOR 
pathway components, proliferation markers and apoptosis marker.  
Further experiments will concern FACS analyses of the above mentioned culture 
conditions which will be treated with 100 nM Rapamycin.  
For quantification of proliferation in cells grown on tissue culture plates and cells 
cultured in collagen gels will use BrdU incorporation assays with FACS analyses or with 
immunofluorescence analyses.  
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6.1 Reagents 
product name company article no. 
2-Glycerophosphate disodium 
salt hydrate Sigma-Aldrich, St. Louis, MO, USA G6251 
2-Mercaptoethanol, min. 98% Sigma-Aldrich, St. Louis, MO, USA M3148 
30% Acrylamide/ Bis-Solution 
37.5:1 (2.6% C) BioRad, Hercules, CA, USA 1610158 
4’,6-Diamidino-2-
phenylindole dihydrochloride 
(DAPI ) 
Sigma-Aldrich, St. Louis, MO, USA 32670 
5-Sulfosalicylic acid dihydrate Sigma-Aldrich, St. Louis, MO, USA S2130 
5x siRNA buffer Dharmacon, Lafayette, CO, USA 
B-
002000-
UB-015 
Acetic acid Sigma-Aldrich, St. Louise, Mo, USA 695092 
Alexa Fluor® 546 phalloidin Invitrogen, Carlsbad, CA, USA A 22283 
Ammonium persulfate (APS) BioRad, Hercules, CA, USA 1610700 
Aprotinin Sigma-Aldrich, St. Louis, MO, USA A1153 
Benzamidine chloride 
Hydrochlorid: Hydrate Sigma-Aldrich, St. Louis, MO, USA B6506 
BioRad - Protein Assay BioRad, Hercules, CA, USA 500-0006 
Blotting Grade Blocker, non-
fat dry milk BioRad, Hercules, CA, USA 170-6404 
Bovine serum albumin (BSA) 
Albumin, Fraction V USB, Cleveland, OH, USA 10857 
Bromophenol blue Merck, Darmstadt, Germany L961422 
Calcium chloride dihydrate 
(CaCl2) 
Merck, Darmstadt, Germany 2382 
Collagen I Gibco-Invitrogen, Carlsbad, CA, USA 
A10483-
01 
Collagenase B Roche Diagnostics, Indianapolis, IN, USA 
11 088 
807 001 
CVT-313 Calbiochem, La Jolla, CA, USA 238803 
DEPC treated water Invitrogen, Carlsbad, CA, USA 10813-012 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, MO, USA D5879 
Dithiothreitol (DTT) Sigma-Aldrich, St. Louis, MO, USA 646563 
DMEM High Glucose (4.5g/l) PAA, Pasching, Austria E15-011 
Dulbecco’s 10x PBS PAA, Pasching, Austria H15-011 
Dulbecco’s 1x PBS PAA, Pasching, Austria H15-002 
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Ethanol absolute for analysis VWR, West Chester, PA, USA 20821.310 
Ethylenediaminetetraacetic 
acid (EDTA) Sigma-Aldrich, St. Louis, MO, USA E5134 
Fetal calf serum (FCS) PAA, Pasching, Austria A15-101 
Glycerol Merck, Darmstadt, Germany 1.04093 
Glycin Sigma-Aldrich, St. Louis, MO, USA G8898 
Goat-α-mouse Alexa Fluor® 
594 Invitrogen, Carlsbad, CA, USA A 11032 
Goat-α-rabbit Alexa Fluor® 
488 Invitrogen, Carlsbad, CA, USA A 11034 
Goat-α-rabbit IgG-h+l Bethyl Laboratories Inc., Montgomery, TX, USA 
A120-
101P 
HEPES USB, Cleveland, OH, USA 16926 
L-glutamine PAA, Pasching, Austria M11-004 
Leupeptin Sigma-Aldrich, St. Louis, MO, USA L2023 
Lipofectamine RNAiMAX Invitrogen, Carlsbad, CA, USA 13778075 
Magnesium chloride 
hexahydrate (MgCl2) 
Merck, Darmstadt, Germany 5833 
Methylcellulose (4000 
centipoises) Sigma-Aldrich, St. Louis, MO, USA M0512 
Mounting medium Vector Laboratories Inc., Burlingame, CA, USA H-1000 
Nonidet-P40 (NP40) USB,Cleveland, OH, USA 19628 
OptiMEM I Gibco-Invitrogen, Carlsbad, CA, USA 31985 
PageRuler Prestained Protein 
Ladder Fermentas SM0671 
Paraformaldehyde (PFA) Sigma-Aldrich, St. Louis, MO, USA P6148 
Penicillin Sigma-Aldrich, St. Louis, MO, USA P3032 
Phenyl-methyl-sulfonyl-
fluorid (PMSF) Sigma-Aldrich, St. Louis, MO, USA P7626 
Ponceau S Sigma-Aldrich, St. Louis, MO, USA P3504 
Potassium chloride (KCl) Merck, Darmstadt, Germany 1.04936 
Propidium iodide Sigma-Aldrich, St. Louis, MO, USA P4170 
Rapamycin Calbiochem, La Jolla, CA, USA 553211 
RNAse A Sigma-Aldrich, St. Louis, MO, USA R5125 
siRNA Dharmacon, Lafayette, CO, USA 
see 
chapter 
6.3 
Sodium chloride (NaCl) Sigma-Aldrich, St. Louis, MO, USA S9625 
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Sodium citrate tribasic 
dihydrate Sigma-Aldrich, St. Louis, MO, USA C7254 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, St. Louis, MO, USA L4390 
Sodium fluoride (NaF) Fluka-Sigma-Aldrich, St. Louis, MO, USA 71519 
Sodium hydroxide (NaOH) 
pellets Merck, Darmstadt, Germany 1.06498 
Sodium orthovanadate 
(Na3VO4) 
Sigma-Aldrich, St. Louis, MO, USA S6508 
Streptomycin sulfate Sigma-Aldrich, St. Louis, MO, USA S6501 
Tetramethylethylenediamine 
(TEMED) Sigma-Aldrich, St. Louis, MO, USA T9281 
Trichlor acetic adid Merck, Darmstadt, Germany 807 
Trisma Base Sigma-Aldrich, St. Louis, MO, USA T1503 
Triton X 100 Sigma-Aldrich, St. Louis, MO, USA T8787 
Trypan blue STEMCELL Technologies Inc., Vancouver, Canada 07050 
Trypsin 1:250 2.2 U/mg Serva, Heidelberg, Germany 37290 
Trypsin inhibitor Sigma-Aldrich, St. Louis, MO, USA T9003 
Tween 20 BioRad, Hercules, CA, USA 170-6531 
α-4E-BP1 Cell signaling, Danvers, MA, USA 9452 
α-Akt Cell signaling, Danvers, MA, USA 9272 
α-cleaved caspase-3 (D175) 
(5A1E) Cell signaling, Danvers, MA, USA 9664 
α-fibrillarin (C13C3) Cell signaling, Danvers, MA, USA 2639 
α-mTOR Cell signaling, Danvers, MA, USA 2972 
α-p70 S6K Cell signaling, Danvers, MA, USA 9202 
α-p70 S6K T389 (108D2) Cell signaling, Danvers, MA, USA 9234 
α-pAkt S473 (D9E) XP Cell signaling, Danvers, MA, USA 4060 
α-p-H3 S10 Cell signaling, Danvers, MA, USA 9701 
α-pS6 240/244 Cell signaling, Danvers, MA, USA 2215 
α-Raptor Bethyl Laboratories Inc., Montgomery, TX, USA 
A300-
506A 
α-Rictor Bethyl Laboratories Inc., Montgomery, TX, USA 
A300-
459A 
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6.2 Equipment 
product name company article no. 
1.5 ml microcentrifuge 
tubes VWR, West Chester, PA, USA 
211-0015 (Europe) 
20170-038 (North 
America) 
100 mm tissue culture plates Iwaki, Asahi Glass Co LTD, Tokyo, Japan 3020-100 
15 ml centrifuge tubes  Sarstedt, Nümbrecht, Germany 62.554.502 
15-slots comb  BioRad, Hercules, CA, USA 165-3355 
3MM Chr sheets  Whatman, Dassel, Germany 3030 917 
4-well chamber slide  
Lab-Tek®, Nalge Nunc 
International, Naperville, IL, 
USA 
177437 
500 µl microcentrifuge 
tubes  Eppendorf, Hamburg, Germany 0030 121.023 
6-well plate  PAA, Pasching, Austria PAA30006X 
96-well plates  Sterillin, Aberbargoed, Caerphilly, UK 
microtiter plate 
612V96 
lid 642000 
BioPhotometer  Eppendorf, Hamburg, Germany  
Bright-Line hemacytometer  Hausser Scientific, Horsham, PA, USA 3120 
Cellquest Version 6.0 BD Immunocytometry Systems  
CL-XPosure films  Thermo Scientific, Rockford, IL, USA 34089 
cover slide  Thermo Scientific, Waltham, MA, USA  
DXD-10143263 
24x60 mm #1 
CryoTubes™  Nalge Nunc International, Naperville, IL, USA 343958 
cuvette  Sarstedt, Nümbrecht, Germany 67.746 
Eppendorf Centrifuge 
5417R  Eppendorf, Hamburg, Germany  
FACS-tube  BD Falcon™, BD Biosciences, Erembodegem, Belgium 352054 
FACSCalibur  Beckton Dickinson, Franklin Lakes, NJ, USA  
FlowJo Version 7.5.5 Tree Star Inc., Ashland, OR, USA  
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glass slide  Thermo Scientific, Waltham, MA, USA DXD-10143560 
GraphPad Prism 4  GraphPad Software Inc., La Jolla, CA, USA  
Heraeus BBD 6220 
incubators  
Thermo Scientific, Waltham, 
MA, USA  
Kodak Medical X-ray 
Processor 2000  Kodak, Stuttgart, Germany  
light-sensitive Amersham 
Hyperfilms  
GE Healthcare, 
Buckinghamshire, UK  28906837 
Microsoft Excel 2008 Microsoft Corporation, Redmond WA, USA   
Mini-PROTEAN Tetra 
Electrophoresis System Hercules, CA, USA 165-8002 
Mini-Trans-Blot Module  BioRad, Hercules, CA, USA  170-3935 
nitrocellulose membrane  Watman, Dassel, Germany  10401396 
orbital shaker  Rocky® 3D   
Parafilm “M”®  VWR, West Chester, Pa, USA  291-1213 
PET mesh with 120 µm 
mesh size  
Bückmann, Mönchengladbach, 
Germany PET-100/77-32 
pipette-tips  Starlab, Ahrensburg, Germany  
0,1-10 µl S1111-
3000  
1-200 µl S1111-
1006  
101-1000 µl S1111-
2021 
rocking platform  VWR, West Chester, Pa, USA  40000300 
single-use syringe   B Braun, Bethlehem, PA, USA  460 6051 V) 
sterile filtration unit with 
0.2 µm pore size  Sarstedt, Nümbrecht, Germany  83.1822.001 
syringe filter with 0,2 µm 
pore size  Whatman, Dassel, Germany  6809-2122) 
thermomixer comfort Eppendorf, Hamburg, Germany   
v-shaped reservoir  Eppendorf, Hamburg, Deutschland  D5063-85 
watherbath shaker Julabo 
W22 
JULABO Labortechnik GmbH, 
Seelbach, Germany  
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6.3 Used siRNA-pools 
optained from Dharmacon, Lafayette, CO, USA 
 
ON-TARGETplus SMARTpool L-004107-00-0005, Human RAPTOR, 
NM_020761 5nmol 
 
ON-TARGETplus SMARTpool siRNA J-004107-05, RAPTOR 
 Target Sequence UGGCUAGUCUGUUUCGAAA 
 Mol. Wt. 13.414,7 g/mol 
 
ON-TARGETplus SMARTpool siRNA J-004107-06, RAPTOR 
 Target Sequence CACGGAAGAUGUUCGACAA 
 Mol. Wt. 13.429,8 g/mol 
 
ON-TARGETplus SMARTpool siRNA J-004107-07, RAPTOR 
 Target Sequence AGAAGGGCAUUACGAGAUU 
 Mol. Wt. 13.414,9 g/mol 
 
ON-TARGETplus SMARTpool siRNA J-004107-08, RAPTOR 
 Target Sequence UGGAGAAGCGUGUCAGAUA 
 Mol. Wt. 13.429,8 g/mol 
 
ON-TARGETplus SMARTpool L-016984-00-0005, Human RICTOR, 
NM_152756, 5nmol 
 
ON-TARGETplus SMARTpool siRNA J-016984-05, RICTOR 
 Target Sequence GACACAAGCACUUCGAUUA 
 Mol. Wt. 13.414,9 g/mol 
 
ON-TARGETplus SMARTpool siRNA J-016984-06, RICTOR 
 Target Sequence GAAGAUUUAUUGAGUCCUA 
 Mol. Wt. 13.384,9 g/mol 
 
ON-TARGETplus SMARTpool siRNA J-016984-07, RICTOR 
 Target Sequence GCGAGCUGAUGUAGAAUUA 
 Mol. Wt. 13.414,9 g/mol 
 
ON-TARGETplus SMARTpool siRNA J-016984-08, RICTOR 
 Target Sequence GGGAAUACAACUCCAAAUA 
 Mol. Wt. 13.399,9 g/mol 
 
ON-TARGETplus Non-targeting Pool D-001810-10-05, 5nmol 
 
 Catalog Item D-001810-10-05 
ON-TARGETplus Non targeting Pool 
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6.4 Buffers and solutions 
Trypsin EDTA solution (TE):  2200 U trypsin  
2% Na EDTA pH 7.4  
 
Antibiotics stock solution:  10 g/l streptomycin sulfate 
6 g/l penicillin 
10% 10x PBS 
 
DMEM with 10% FCS:  DMEM high glucose (4.8 g glucose/l) 
10% FCS 
60 mg/l penicillin 
100 mg/l streptomycin sulfate 
2 mM l-gluatmine 
 
Methylcellulose:   1.5% (w/v) Methylcellulose 
in DMEM supplemented with 2 mM l-glutamine 
 
DMEM with 2% FCS:  DMEM high glucose (4.8 g glucose/l) 
2% FCS 
60 mg/l penicillin 
100 mg/l streptomycin sulfate 
2 mM l-gluatmine 
 
DMEM with 10% FCS w/o antibiotics: DMEM high glucose (4.8 g glucose/l) 
10% FCS  
2 mM l-gluatmine 
 
NP40 lysis buffer:   40 mM Hepes pH 7.5  
120 mM NaCL 
1 mM EDTA pH 8.0  
10 mM 2-glycerophospate  
50 mM NaF   
0.5mM Na3VO4 
1% NP40 
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PIM:     2 µg/ml Leupeptin  
2 µg/ml Aprotinin 
0,3 µg/ml Benzamidine chloride 
10µg/ml Trypsin inhibitor 
 
4x protein sample buffer:  200 mM Tris pH 6.8  
400 mM DTT 
8% SDS 
0.4% Bromphenol blue 
40% Glycerol 
 
Buffer B pH 8.8:   1.5 M Tris pH 8.8 
0.4% (v/v) SDS 
 
APS:     10% (w/v) APS  
 
Buffer C pH 6.8:   0.5 M Tris pH 6.8 
0.4% (v/v) SDS 
 
10x electrophoresis buffer:  250 mM Tris   
1.94 M glycine 
1% (w/v) SDS 
 
1x electrophoresis buffer:  10% (v/v) 10x electrophoresis buffer 
 
Harlow 1:    48 mM Tris  
386 mM glycine 
0,1% (w/v) SDS 
20% (v/v) methanol 
 
10x Ponceau S:   2% (w/v) Ponceau S 
30% (w/v) trichlor acetic acid 
30% (w/v) sulfosalicylic acid 
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1x Ponceau S:    10% (v/v) 10x Ponceau S 
 
10x TBS:    1.5 M NaCL    
0.5 M Tris pH 7.4 
 
1x TBS-T:    10% (v/v) 10x TBS 
0.1% (v/v) Triton X-100 
 
5% blocking solution:  5% (w/v) milk powder 
1x TBS-T 
 
TBS-T, 5% BSA:   5% (w/v) bovine serum albumine 
1x TBS-T 
 
stripping buffer:   60 mM Tris pH 6.7 
2% SDS 
0.7% 2-mercaptoethanol 
 
collagenase B:    0,10 g/l CaCl2  
0,10 g/l MgCl2 hexahydrate  
0,20 g/l KCl 
1x PBS w/o Ca2+, Mg2+, K  
 
PI:     1.176 mg/ml of trisodiumcitrat 
0.25 mg/ml of RNAse A  
0.05 mg/ml of propidium iodide 
0.1% Triton X-100   
 
4% Paraformaldehyde pH 7.4: 4% (w/v) PFA    
1% 1M NaOH   
10% 10x PBS    
 
1x TBS-Tween:   0.5% Tween-20 
1x TBS 
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1x PBS-Tween:   0.5% Tween-20  
1x PBS 
 
Blocking buffer:   5% FCS 
0.3% Triton X-100 
1x PBS  
 
Antibody Dilution Buffer:  1% BSA   
0,3% Triton X-100 
1x PBS 
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6.5 List of abbreviations  
% percentage 
°C degree Celsius 
2D two-dimensional 
3D three-dimensional 
4E-BP1 eukaryotic initiation factor 4E (eIF4E) binding protein 1 
ADPKD autosomal recessive polycystic kidney disease 
AKT v-Akt murine thymoma viral oncogene homolog  
AMP adenosine monophosphate 
AMPK AMP kinase 
APS ammonium persulfate 
ATCC American Type Culture Collection 
BAD Bcl-2-associated death promoter 
BM basement membrane 
BME basement membrane extract 
BrdU Bromodeoxyuridine 
BSA bovine serum albumin 
c cells 
cDNA chromosomal DNA 
cm centimeter 
COX-2 cyclooxygenase-2 
DAPI 4',6-diamidin-2'-phenylindol- dihydrochlorid  
DMEM Dulbecco's Modified Eagle Medium  
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
ECL enhanced chemilumescence 
ECM extracellular matrix 
EDTA ethylene 
EGF epithelial growth factor 
eIF4E eukaryotic translation initiation factor 4E 
ERK extracellular-signal-regulated kinase 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FKBP12 FK506-binding protein 12 
FOXO forkhead box protein 
FRB domain FKBP12-rapamycin binding domain 
FSC forward scatter 
g gram 
g g-force 
GAP GTPase activating protein 
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Gβl/mLST8 G-protein β-subunit like protein/mammalian LST8 
H2A Histone H2A 
H2B Histone H2B 
H2Odest. Aqua dest. 
H3 Histone H3 
H4 Histone H4 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
IMR90-2D-dense IMR-90 cultured dense in 2D 
IMR90-2D-sparse IMR-90 cultured sparse in 2D 
IMR90-cell-CG IMR-90 cultured as single-cell suspension collagen gel 
IMR90-sph IMR-90 cultured as spheroids 
IMR90-sph-CG-1h spheroids cultured for 1 hour in collagen gel 
IMR90-sph-CG-2d spheroids cultured for 2 days in collagen gel 
IRS insulin receptor substrate 
k-d knock down 
kDa kilodalton 
l litre 
LAM lymphangioleiomyomatosis 
M Mol 
mA milli ampere 
MAPK mitogen-activated protein kinase 
MC Methylcellulose 
mg milligram 
min. minutes 
ml millilitre 
mM millimol 
mm millimetre 
mm2 square millimetres 
mm3 cubic millimetres 
mRNA messenger RNA 
mSin1 mammalian stress-activated protein kinase interacting protein 1 
MT1-MMP Matrix metalloproteinase-14 
mTOR mammalian target of rapamycin 
mTORC 1 mammalian target of rapamycin complex 1 
mTORC 2 mammalian target of rapamycin complex 2 
MW molecular weight 
nMol nano mol 
NP40 Nonidet P40 
NTC non-targeting control 
p70 S6K ribosomal protein S6-kinase, 70 kDa 
pAKT phosphorylated v-Akt murine thymoma viral oncogene homolog  
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PBS phosphate buffered saline 
PDGF platteled derived growth factor 
PDK1 3-phosphoinositide dependent protein kinase-1 
PET polyethylene terephthalate 
PFA paraformaldehyde 
pH potentiometric hydrogen ion concentration  
PI propidium iodide 
PI3K phosphatidylinositol 3-kinase 
PIKK phosphoinositide 3-kinase related kinase 
PIM protease inhibitor mix 
PMSF phenylmethylsulfonyl fluoride  
PP2A protein phosphatase 2A 
PRAS40 proline-rich AKT substrate of 40 kDa 
PRR5/protor proline-rich protein 5/protein observed with rictor 
pS6 phosphorylated ribosomal protein S6 
raptor regulatory associated protein of mTOR  
Ras rat sarcoma 
rH relative humidity 
Rheb ras-homologe enriched in brain 
rictor rapamycin insensitive companion of mTOR  
RNA ribonucleic acid 
rpm rounds per minute 
S serine 
S6 ribosomal protein S6  
S6K1 ribosomal protein S6 kinase 1 
S6K2 ribosomal protein S6 kinase 2 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec. seconds 
siRNA small interfering RNA 
sph spheroid 
SSC side scatter  
STK11/LKB1 Serine/threonine kinase 11 
T threonine 
TBS tris buffered saline 
TBS-T tris buffer saline + Triton X-100 
TE trypsin-EDTA 
TEMED N, N, N', N'-tetramethylethylenediamine  
TOS motif TOR signalling motif 
TSC tuberous sclerosis complex 
TSC1 tuberous sclerosis complex 1 
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TSC2 tuberous sclerosis complex 2 
U enzyme unit 
V volt 
v/v volume/volume 
VEGF vascular endothelial growth factor 
w/v weight/volume 
µ micro 
µg microgram 
µl microliter 
µm micrometer 
µM micromol 
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